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ABSTRACT 
 
Hepatitis B is a global health problem that kills about 600 000 people annually. It is an 
infectious disease caused by the Hepatitis B Virus (HBV), which infects the liver and 
leads to liver inflammation and secondary complications such as cirrhosis and 
Hepatocellular Carcinoma (HCC). The available therapies are only partially effective and 
are associated with adverse side effects and viral drug resistance. RNA interference 
(RNAi) pathway is a gene silencing pathway found in diverse living systems including 
mammals. Harnessing of this pathway to inhibit HBV replication has shown a lot of 
promise, with highly effective anti-HBV RNAi activator sequences designed. However, 
the lack of safe and efficient delivery and expression systems for these sequences is one of 
the obstacles that need to be overcome before RNAi effectors can reach clinical 
application. For easy assessment of transduction efficiency, Helper Dependent Adenoviral 
vectors (HDAd) expressing β-galactosidase (encoded by lac Z gene) are commonly used 
to deliver anti-viral RNAi activators. However, this reporter protein has been blamed for 
induction of innate immune response and concomitant clearance of the HDAds by the 
host. For the first time, this study explored the use of lac Z-deficient HDAds to deliver 
anti-HBV RNAi activators expressed under the control of a liver-specific 
phosphoenolpyruvate carboxykinase (PEPCK) promoter. HDAd expressing Firefly 
luciferase resulted in a significant luminescence detected in cell culture lysates and a 
sustained bioluminescence in mice. HDAds expressing anti-HBV sequences transduced 
the liver efficiently and did not induce a pronounced inflammatory response or liver 
toxicity in mice. However, this did not translate into maximal anti-HBV sequence 
expression and HBV replication inhibition in vitro and in vivo. This suggests that the 
PEPCK promoter is inadequate for RNAi activator expression. This study highlights the 
importance of careful RNAi activator regulatory elements selection and presents the 
therapeutic potential and utility of HDAd vectors for hepatotropic delivery of antiviral 
sequences with markedly attenuated immune response stimulation and toxicity. For 
improved anti-HBV RNAi activator expression and HBV knockdown, a different liver 
specific promoter mouse transthyretin receptor (MTTR) promoter is currently being 
investigated in our lab.  
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CHAPTER 1 
 
1 INTRODUCTION 
1.1 Hepatitis B 
 
Hepatitis B is a global health problem that affects millions of people, with a high 
incidence found in areas such as East Asia and Sub-Saharan Africa (WHO, 2016). This is 
an infectious disease caused by the Hepatitis B Virus (HBV), which infects the liver and 
leads to liver inflammation. HBV is mainly transmitted through infectious blood or other 
body fluids either percutaneously, sexually or perinatally. Secondary complications of 
HBV infection include acute and chronic infections, cirrhosis and Hepatocellular 
Carcinoma (HCC). HBV accounts for the infection of approximately 2 billion individuals 
worldwide, of which 240 million are chronic cases that lead to an estimated 600 000 
individual deaths each year (Mueller et al., 2015, Ott et al., 2012). The prevention of, and 
effective therapies against HBV infection are key to reducing the spread of this condition. 
 
There has been a safe and effective vaccine available against HBV infection since 1982. 
Nevertheless, infant vaccine administration is preferred as soon as possible after birth. 
During 1991, the World Health Organisation (WHO) suggested the implementation of 
mass immunization against HBV infection in all countries. This resulted in the decrease in 
HBV infection occurrence among infants, children and young adults in various countries. 
However, due to several countries not implementing the suggested mass vaccination 
program, HBV remains prevalent in a large number of individuals [reviewed in 
(Lavanchy, 2004, MacLachlan and Cowie, 2015)].  
 
Current licensed treatments of Hepatitis B make use of conventional interferon-α (IFN-α) 
or pegylated IFN-α, with finite duration that has both antiviral activity and 
immunomodulatory actions. Furthermore, these treatments involve long duration 
nucleoside and nucleotide analogues that are inhibitors of viral reverse transcriptase and 
DNA polymerase. Nucleoside and nucleotide analogues, which include Lamivudine, 
Adefovir dipivoxil, Entecavir, Telbivudine, or Tenofovir, have been approved for the 
treatment of chronic HBV infection, with Lamivudine being the most widely administered 
drug [Reviewed in (Weinberg and Arbuthnot, 2010, Tang et al., 2014)]. However, 
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prolonged treatment with interferon-α (IFN-α) and nucleoside and nucleotide analogues 
monotherapy can bring about viral drug resistance and adverse side effects such as hepatic 
damage, effectiveness in only 50 % of patients and is also expensive. Major side effects 
and drug resistance most frequently occurs in interferon-α and Lamivudine treated 
individuals, respectively (Perrillo, 2004, Lok, 2008). The emerging viral drug resistance is 
usually a result of the mutations within the viral polymerase gene. Despite cross-resistance 
of other agents such as Entecavir, a combination of nucleoside and nucleotide analogs 
with a high genetic barrier to resistance can prevent or limit the emergence of viral drug 
resistance [Reviewed in (Weinberg and Arbuthnot, 2010, Keeffe et al., 2008)]. IFN-α has 
a broad antiviral activity and has a different mechanism to that of nucleosides and 
nucleotides analogues, for it is not associated with the blocking of a specific part in the 
viral replication process. As a result, IFN-α functions are not influenced by drug resistant 
mutations. Nevertheless, the available therapies are only partially effective against the 
virus and therefore do not completely eradicate the virus resulting in the reactivation of 
HBV (Lok, 2008, Perrillo, 2004).  The challenges of current treatments prompted the need 
for new Hepatitis B therapies. 
 
1.2 RNA interference  
 
The interference with viral gene expression has been proven to be an effective method in 
controlling viral infections (Peng et al., 2005, Jacque et al., 2002, Yang et al., 2013). RNA 
interference (RNAi) is a pathway triggered by double-stranded RNA (dsRNA) and 
functions as a regulatory and self-defense mechanism in eukaryotic cells. The conserved 
RNAi pathway has been found to occur in a wide range of organisms including animals 
and plants (Elbashir et al., 2001). The first discovery of the RNAi pathway was by 
Andrew Fire and Craig Mello, whereby induced gene silencing by dsRNA was observed 
in the Caenorhabditis elegans nematode (Fire et al., 1998). This discovery provided the 
first glimpse into controlling the expression of target messenger RNA (mRNA) using the 
RNAi mechanism. The most studied RNAi pathway is known as the mammalian 
microRNA (miR) pathway. The first step of this pathway involves the transcription of 
miR-encoding genes by RNA polymerase II within the nucleus to give rise to a hairpin-
structured primary miR (pri-miR). The pri-miR is then processed to produce the 60-80 
nucleotides (nt) hairpin structured precursor miR (pre-miR) by the microprocessor 
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complex comprised of Drosha (RNase III) and DiGeorge Critical Region 8 (DGCR8 - 
Drosha double stranded RNA binding domain partner). The pre-miR is then exported from 
the nucleus into the cytoplasm by nuclear karyopherin exportin-5. Pre-miRs are further 
processed to form mature-miR duplexes of 21-23 nt in length by Dicer (an RNase III 
protein) and TRBP (TAR - double stranded RNA -binding protein) (Han et al., 2009, Zeng 
et al., 2003, Denli et al., 2004). This is followed by the integration of the 21-23 nt miR 
duplexes into the RNA induced silencing complex (RISC) that contains an Argonaute 2 
protein. This complex selects and retains one strand as a guide strand and releases the 
remaining passenger strand. The guide sequence is used for sequence-specific recognition 
of the target mRNA and through complementary base pairing pairs with the target mRNA 
(Denli et al., 2004, Hammond et al., 2001). The guide strand can have a partial 
complementarity with the sequences of the targeted mRNA 3’ untranslated region (UTR), 
which results in the translation inhibition. On the other hand, should the guide strand have 
complete complementarity, then the mRNA can be targeted for degradation (Khvorova et 
al., 2003, Zeng and Cullen, 2003, Zeng and Cullen, 2005, Zeng et al., 2002, Zeng et al., 
2003). 
 
The exploitation of the RNAi pathway for the sequence specific silencing of genes is well 
established as a research tool in gene therapy, especially as a therapeutic method for viral 
disease treatments (Elbashir et al., 2001, McBride et al., 2008, McCaffrey et al., 2003, 
Peng et al., 2005). A number of studies have shown the successful therapeutic application 
of the RNAi technology for the treatment of serious viral diseases like Human 
Immunodeficiency Virus (HIV) and Hepatitis C (HCV) (Gitlin et al., 2002, Jacque et al., 
2002, Lee et al., 2002, Wilson et al., 2003). This is achieved by introducing mimics of 
pre-miR [short hairpin RNA (shRNA)], pri-miR [artificial pri-miR (pri-miR)] or mature 
miR duplexes [short interfering RNA (siRNA)] in the host to target viral mRNA 
sequences (Dykxhoorn et al., 2006, Keck et al., 2009).  
 
1.2.1 HBV as a potential target for RNA interference   
 
HBV is an enveloped, noncytopathic DNA virus that belongs to the Hepadnaviridae 
family of hepatotropic viruses and has been known to infect both humans and 
chimpanzees (Lyons et al., 2012). The HBV genome is 3.2 kb in length and contains a 
relaxed circular and partially double stranded DNA (rcDNA) (Figure 1.1). In infected 
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hepatocytes, the rcDNA is converted to covalently closed circular DNA (cccDNA). The 
formed cccDNA acts as the template for the production of pregenomic RNA (pgRNA) 
used for viral replication and all viral RNAs important for viral protein synthesis and viral 
assembly. The difficulty associated with eliminating cccDNA from infected hepatocytes is 
the main reason for the ineffectiveness of many antiviral therapeutics. The HBV genome 
consists of an evolved organization of conserved protein coding and regulatory regions. It 
encodes four overlapping open reading frames (ORF). The ORF's include the pre-core 
(PC) and core (C) ORF, Polymerase ORF (P), the Surface (S) ORF that codes for envelope 
proteins pre-S1, pre-S2 and S, and lastly the X ORF that encodes for multifunctional X 
protein (HBx). It also contains a promoter and enhancers (regulatory elements), as well as 
signals required for polyadenylation and encapsidation. The conserved regions can encode 
for multiple proteins and for the cis-elements of HBV required for viral replication (Beck 
and Nassal, 2007, Araki et al., 1989, Tang et al., 2014). The HBV genome consist of a 
single transcription signal, this signal results in the presence of the common 3’ end in the 
HBV transcripts that includes the HBx. This arrangement of the HBV genome limits the 
viral sequences flexibility, thereby making the HBx a suitable target for gene silencing and 
antiviral therapies that are based on nucleic acid hybridisation. It enables the degradation 
of multiple HBV viral mRNA transcripts with a single anti-HBV RNAi activator, making 
it an ideal target for RNAi based therapies [(Jia et al., 2007, Carmona et al., 2006), Figure 
1.1]. 
 
The use of RNAi-based therapies for the gene silencing and inhibition of HBV gene 
expression by targeting specific genes of interest has been extensively studied (Wooddell 
et al., 2013, McCaffrey et al., 2003). As a result of the cytoplasmic site of action and their 
small size, short interfering RNA (siRNAs) has distinct advantages. These include easy 
dose control, production and delivery. In addition, siRNAs can be subjected to chemical 
modifications to improve stability, specificity and safety by reducing immunostimulatory 
effects and hepatotoxicity (Wooddell et al., 2013, Marimani et al., 2013, Marimani et al., 
2015). Previous studies have shown the ability of siRNAs to effectively inhibit HBV gene 
expression and replication in both in vitro and in vivo applications (Giladi et al., 2003, Jia 
et al., 2007, McCaffrey et al., 2002). Giladi and colleagues showed the successful 
inhibition of HBV viral gene expression and replication through the targeting of the HBV 
surface antigen. The inhibition of viral gene expression was observed in both HepG2.215 
cells and a HBV mouse model (Giladi et al., 2003). However, the inhibition of gene 
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expression by siRNAs is short-lived and requires repeated administration for a sustained 
suppression of viral replication (McCaffrey et al., 2002, Giladi et al., 2003, Marimani et 
al., 2013). 
 
 
Figure 1.1: HBV genome organisation  
The HBV genome is a partially double stranded genome with cis-acting elements 
presented by the circles and squares that regulate HBV transcription. The viral genome co-
ordinates are given relative to the single Eco RI restriction site. The surrounding arrows 
indicate the viral open reading frames (with initiation codons) of the surface, core, 
polymerase and HBx, encompassing the entire HBV genome. The four outer arrows 
indicate the HBV transcripts which have a common 3′ polyadenylation site. As well as, the 
targeted site 5, 8 and 9 within the HBx for the RNAi pri-miR 31/5, pri-miR 31/589 and pri-
miR 122/5 activator cassettes [Adapted from (Ivacik et al., 2011, Mowa et al., 2012)]. 
 
Therefore studies have evaluated the use of expressed shRNAs and artificial pri-miRs in 
vitro and in vivo for a sustained inhibition of gene expression in HBV infection models. 
These expressed activators have the advantage of being more sustainable and compatible 
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with more efficient viral vector delivery systems (Grimm and Kay, 2006, Grimm et al., 
2006, Jenke et al., 2008, McCaffrey et al., 2003, Wooddell et al., 2013). Effective 
inhibition of HBV gene expression was observed by Carmona and colleagues using anti-
HBV shRNA cassettes which target specific regions within the HBx sequence (Carmona et 
al., 2006). In addition McCaffrey and colleagues showed efficient HBV inhibition in vitro 
and in vivo using anti-HBV shRNA cassettes targeting the HBV mRNAs of the 
pregenominc RNA, the core antigen and polymerase. However, shRNAs can only be 
effectively expressed from Polymerase III (Pol III) promoters e.g. U6 small nuclear RNA 
and Human ribonuclease P RNA component H1 (U6 and H1 promoters) (Jenke et al., 
2008, McCaffrey et al., 2003), which have been previously associated with in vivo 
cytotoxicity and tissue damage. These toxic effects were as a result of the saturation of the 
endogenous RNAi pathway, caused by the overexpression of shRNA by Pol III promoters. 
Furthermore, Pol III promoters are non-tissue specific and therefore have robust activity 
across several cell types (Ely et al., 2008, Giering et al., 2008, Grimm and Kay, 2006, 
Grimm et al., 2006, Grimm et al., 2010). Expression of shRNAs from cytomegalovirus 
(CMV) Polymerase II (Pol II) promoter demonstrated HBV knockdown, but the efficiency 
of the silencing was found to be unpredictable and variable (Li et al., 2007).   
 
To alleviate this problem, antiviral expression cassettes consisting of the Pol II 
transcription regulatory elements upstream of the pri-miR mimic's encoding sequence 
were constructed. This strategy has successfully been used against HBV infection and has 
shown to be less toxic in vitro and in vivo (Ely et al., 2008, Mowa et al., 2012, Mowa et 
al., 2014, Ivacik et al., 2015). Moreover, Pol II expression allows for tissue specificity 
and/or can be inducible for precise transgene expression (Maczuga et al., 2012, McBride 
et al., 2008). To enhance silencing efficiency and avoid viral escape, pri-miR mimics can 
be engineered to express multiple (polycistronic) anti-HBV sequences that can target 
several specific sites within the HBV genome (Ely et al., 2009, Ely et al., 2008). Zeng and 
colleagues have previously shown that the substitution of the guide sequence in both 
naturally occurring pri-miR 30 and pri-miR 21 with a synthetic sequence produced a novel 
miR sequence that was complementary to the target site. These monocistronic sequences 
inhibited the expression of specific human genes, by either translation inhibition or mRNA 
degradation (Zeng and Cullen, 2003, Zeng et al., 2002, Zeng et al., 2003). Recently, pri-
miR 106 and pri-miR 155 polycistronic expression systems have been engineered. Pri-miR 
106-cluster demonstrated potent inhibition of HIV-1 replication and pri-miR155-cluster 
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increased the inhibition of the targeted BIC RNA [non-coding RNA that causes lymphoma 
by cooperating with c-myc transcription factor] (Aagaard et al., 2008, Chung et al., 2006). 
 
To further investigate the application of pri-miR mimics in HBV replication inhibition, 
CMV promoter driven, monomeric and trimeric mimics of naturally occurring pri-miR 31 
and pri-miR 122 were constructed within the Antiviral Gene Therapy Research Unit 
(AGTRU). The backbone of pri-miR 122 was selected due to its dominant expression in 
the liver (Chang et al., 2004). Pri-miR 31 backbone is also well suited for the RNAi 
therapeutics design as it is efficiently processed by Drosha (Zeng and Cullen, 2005). The 
anti-HBV pri-miRs were generated by replacing the guide and complementary sequence 
with the anti-HBx sequences in the structure of pri-miR 31 to generate monocistronic pri-
miR 31/5 and polycistronic pri-miR 31/589 or pri-miR 122 to generate monocistronic pri-
miR 122/5 (Figure 1.1). The use of these cassettes demonstrated efficient knockdown of 
HBV gene expression and were found to be safer in mice. The CMV promoter is one of 
the strongest promoters and has been widely applied in in vivo expression of therapeutic 
genes in various tissues including the liver of mice. Even though the results obtained 
indicated efficient HBV silencing, the CMV promoter is not liver specific. Hence, it is 
capable of driving high levels of transgene expression in non-hepatic tissue (Ely et al., 
2009, Ely et al., 2008, Ivacik et al., 2015). In addition, the expression and activation of the 
CMV promoter in hepatocytes are Nuclear factor-kappaB (NF-ĸB) dependent. However, 
NF-ĸB is absent in mouse hepatocytes. Hence, strong short-term expression (1 week after 
delivery) of transgenes was observed, followed by reduced gene silencing (barely 
detectable) after 1-6 weeks (Loser et al., 1998, Mowa et al., 2014). Therefore, the CMV 
promoter would not be suitable for therapeutic application against chronic Hepatitis B. 
 
Alternatively, studies have investigated the use of vectors bearing Phosphoenolpyruvate 
carboxykinase (PEPCK) promoter which are predominately active within the liver. Tissue-
specific activity of the PEPCK promoter was analysed by Song et al., (2006) in vitro using 
plasmids expressing Firefly luciferase (Fluc) from a PEPCK promoter. The PEPCK 
promoter resulted in a significant Fluc expression in different liver cell lines. Song and 
colleagues further explored the use of the PEPCK promoter to improve liver specific 
cancer therapy (hepatocellular carcinoma). The experiment entailed the design of a liver 
specific expression cassette with a human telomerase reverse transcriptase (hTERT) RNA-
targeting specific trans-splicing ribozyme. The results showed liver specific anti-cancer 
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gene activity by effectively inducing cytotoxicity in the liver cancer cells and decreased 
activity in non-liver cancer cells (Song and Lee, 2006).  
 
On the other hand, studies have investigated the use of vectors bearing the PEPCK 
promoter for long-term transgene expression (Brunetti-Pierri et al., 2007, Mian et al., 
2004). Main and colleagues investigated the design of vectors expressing human ornithine 
transcarbamylase (hOTC) from a PEPCK promoter in the presence or absence of a 
Woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) downstream of 
the hOTC Complementary DNA (cDNA), to enable long-term correction of OTC 
deficiency in mice. A long-term rectification of orotic aciduria was observed for 12 
months (length of experiment) with considerable liver OTC activity (expression) in the 
absence of chronic liver toxicity (Mian et al., 2004). Brunetti-Pierri and co-workers 
persued the investigation of the expression of α-fetoprotein (bAFP) from a PEPCK 
promoter in non-human primates. The results indicated long-term (> 1 year) and stable 
hepatic expression of the bAFP transgenes in non-human primates in the absence of 
chronic hepatotoxicity (Brunetti-Pierri et al., 2007, Brunetti-Pierri et al., 2006). This long-
term transgene expression provoked the investigation towards the application of this 
PEPCK promoter for HBV treatment. Hence, this study aimed to design PEPCK promoter 
driven pri-miR 31 mimics to achieve liver specific expression and HBV replication 
knockdown. 
 
In addition to finding the most efficient regulatory elements for anti-HBV RNAi activator 
expression, the lack of an effective and safe in vivo delivery system for these highly 
effective sequences remains one of the biggest challenges in anti-HBV gene therapy 
(Aagaard and Rossi, 2007). Hence, this study also focuses on finding an efficient and safer 
delivery system for anti-HBV RNAi activators. 
 
1.3 Delivery systems for antiviral RNAi activators 
 
For successful gene therapy, suitable amounts of therapeutic sequences need to be 
transported to the targeted tissue without significant toxicity. For RNAi activator 
sequences to be effectively transported to the liver, vectors are required to deliver the anti-
HBV effector sequences directly to the hepatocytes after administration. A sustained HBV 
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silencing that can be achieved with a single administration is the optimal target for vector 
based therapeutics. Hence, finding a suitable and safe delivery system remains one of the 
biggest obstacles (Lundstrom and Boulikas, 2003).  
 
Physical, viral and chemical/non-viral methods can be used to deliver therapeutic 
sequences. Physical delivery is performed by applying a force that allows the permeation 
of the cell membrane for intracellular nucleic acid translocation. This can be applied 
through needle injection, electroporation, hydrodynamic delivery or ultrasound. These 
methods have been used successfully in pre-clinical studies, however most are less 
efficient and unsafe in a clinical setting [reviewed in (Kaneda and Tabata, 2006, 
Villemejane and Mir, 2009)]. The second approach is non-viral (NVVs) methods, whereby 
the desired transgenes are transported into the cell as a complex with synthetically 
engineered or naturally occurring compounds (Deng et al., 2009). The use of these vectors 
for HBV treatment for delivery of RNAi activators to the liver has proven to be very 
useful (Carmona et al., 2009, Marimani et al., 2013, Marimani et al., 2015, Morrissey et 
al., 2005). However, the NVV’s are less efficient in transfecting cells and are more 
compatible with small synthetic siRNAs than expressed RNAi activators. To improve the 
in vitro and in vivo transduction efficiency, further studies were performed using a third 
approach, namely viral vectors. Experiments conducted have found viral vectors such as 
Adeno-associated viral vectors (AAV), Lentiviral vectors (LV) and Adenoviral vectors 
(AdV) to be more efficient and can be targeted to desired tissue (Tomanin and Scarpa, 
2004, Uchida et al., 2002, Breyer et al., 2001). 
 
1.3.1 Viral vectors  
 
1.3.1.1 Lentiviral vectors 
 
Lentiviral vectors (LV’s) are recombinant vectors that integrate into the host genome, 
thereby providing a means of long-term gene expression. LV’s have been derived from 
human immunodeficiency virus type 1 (HIV-1) and have been applied in the RNAi-based 
HBV therapy. They have a larger transgene cloning capacity compared to that of AAV’s 
and can allow efficient transgene delivery. These vectors are capable of transducing a 
wide range of proliferating and non-proliferating cells, which enables long-term 
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expression of transgenes in hepatocytes in vitro and in vivo (Ivacik et al., 2015, Nguyen et 
al., 2005, Nguyen et al., 2002). 
 
The ability of LV’s to transduce a variety of tissues, especially non-dividing cells has 
prompted new possibilities and applications of LV’s in gene therapy. The first 
demonstrations of the long-term therapeutic potential of Lentiviral vectors was performed 
on many central nervous system cell types through the injection of these vectors into 
animal models. This led to the idea that LV’s could represent a possible tool for liver 
studies, as the liver is composed of non-dividing, active and highly differentiated cells. 
Further studies demonstrated the efficient transduction in murine models using LV’s for 
numerous hereditary metabolic liver diseases (Nguyen et al., 2002, Park et al., 2000, 
Pfeifer et al., 2001, Rittelmeyer et al., 2013, Kubo and Mitani, 2003). In Hepatitis B and C 
virus infection cases, the liver cells transduced with the LV carrying transgenes can 
suppress the replication of HBV and HCV. Ivacik and colleagues presented the first 
efficient silencing of HBV gene expression using RNAi-activating anti-HBV sequences 
delivered with LV’s in transgenic HBV mice (Ivacik et al., 2015). However, in vivo 
testing in murine models indicated that hepatocyte LV transduction efficiency is less than 
that of neurons. As a result, ex vivo methodologies that yielded high transduction 
efficiency and hepatocyte survival are considered for the gene therapy based treatment of 
liver disease using LVs. But in vitro and ex vivo gene delivery is still limited by the low 
titers produced during viral production (Kubo and Mitani, 2003, Nguyen et al., 2002). 
Although performing viral production with transient transfection is capable of increasing 
the titers, the method itself is burdensome and scaling up is difficult [reviewed in (Matrai 
et al., 2010)]. 
 
Another concern is the clinical safety of LVs, which focuses on potential oncogene 
activation and/or tumor suppressor genes as a result of the LV integration into the host 
genome. As well as, the pathogenicity that may be caused by the recombination and 
regeneration of the wild type virus, HIV-1 from which LV’s have been derived, in patients 
with an infectious retrovirus such as HIV-1 or HIV-2 (Matrai et al., 2010, Manjunath et 
al., 2009). 
 
 
CHAPTER 1  MSc Dissertation 2017 
11 | P a g e  
 
 
1.3.1.2 Adeno-associated viral vectors  
 
As a result of the lack of pathogenicity of AAV’s, these viruses were seen as having no 
medical significance. Hence, lack of AAV biology understanding prevented AAV’s broad 
use as delivery vectors. But after recent extensive research, promising results were 
obtained, showing stable tissue transduction and minimal immune stimulation by AAVs. 
The non-pathogenicity, viral persistence, non-significant immune response induction and 
existence of a large number of serotypes provoked further studies into using these vectors 
as a delivery system for gene therapy (Wang et al., 2010, Wang et al., 2004).  
 
Adeno-associated virus is an icosahedral, non-enveloped, single-stranded DNA virus that 
is small in size (genome size of ± 4.7 kb) with a capsid diameter of 18-25 nm and a 
genome of either a plus or minus polarity. This virus is a non-pathogenic parvovirus that 
requires a co-infection with a helper virus, either adenovirus or herpesvirus to replicate 
and spread. In the AAV vector, 96 % of the viral coding genes (± 4.4 kb) have been 
deleted, leaving both ends of the AAV with the inverted terminal repeats (ITR’s). The 
ITR’s contain the cis-element that is required for replication and genome packaging. The 
AAV vector therefore contains only the gene of interest and ITR’s. In turn, this further 
reduced the possibility of immune simulation by the viral proteins (Kaplitt et al., 1994, 
Srivastava et al., 1983, Xiao et al., 1996).  
 
Thirteen AAV serotypes have been identified in humans (AAV2, -3, -5 and -6) and non-
human primates (AAV1, -4, and -7 to -13). Furthermore, more than 100 new and unique 
AAV variants have been isolated in human and non-human primates. However, serotype 2 
(AAV-2) has been more extensively studied and therefore serves as the model for the 
AAV family (Gao et al., 2004, Rayaprolu et al., 2013, Venkatakrishnan et al., 2013, 
Schmidt et al., 2004). Recent studies have shown that each serotype has different 
structural and functional characteristic and has efficient transduction with long-term gene 
expression in a number of different cell types. These cell types include liver, muscle, lung 
and pancreases.  The first long-term transgene expression using recombinant AAV vectors 
with a lac Z reporter gene (rAAV-lacZ) in vitro (mice muscles cells) and in vivo without 
immune stimulation was observed by Xiao and colleagues (Xiao et al., 1996, Wang et al., 
2004). Furthermore, studies have shown a great reduction in HBV serum titers and mRNA 
present in the liver of transgenic mice by anti-HBV shRNA delivered by three different 
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double stranded Adeno-associated vectors (dsAAV); dsAAV8, dsAAV7 and dsAAV9 
(Chen et al., 2007, Chen et al., 2009). However, despite AAV vectors achieving some 
level of success in highlighting their potential as vectors for clinical application, a number 
of hurdles still need to be overcome. These hurdles include the extremely high viral 
dosages required for efficient transduction and the antibody neutralization of AAV’s due 
to the high prevalence of AAV-2 specific antibodies in humans. Limited knowledge 
behind the mechanism of AAV-host interaction hinders the efficient use of AAV as a 
vector for gene delivery. Furthermore, the smaller size of the AAV genome limits its 
transgene capacity (Nakai et al., 2005, dos Santos Coura, 2008). 
 
1.3.1.3 Adenoviral vectors 
 
Adenoviruses (Ads) are one of the most extensively studied viruses used for gene therapy 
and vaccine development. The discovery of Ads has prompted the interest in broadening 
the knowledge on the Ads genome and their application as delivery vectors. The easy 
production of high viral titers and high, long-term hepatocyte transduction efficiency and 
gene expression (in vivo) without integrating into the host genome, the large DNA insert 
accommodation and ability to transfer genes to a variety of dividing and non-dividing cells 
has drawn great attention to Ads (Croyle et al., 2005, Croyle et al., 2000). Adenoviruses 
are useful delivery vectors for anti-HBV effecter sequences, due to their natural tropism 
for the liver and efficient targeting into hepatocytes (Crowther et al., 2008, Jozkowicz and 
Dulak, 2005). This study therefore investigated the use of Adenoviral vectors for the 
delivery of anti-HBV pri-miR sequences.   
 
Adenoviruses belong to the Adenoviridae family, and are non-enveloped, icosahedral 
particles that are 70-90 nm in diameter. The Ad is surrounded by an outer protein capsid 
that is composed of capsomeres that consist of 252 subunits and are made up of 3 major 
proteins. These proteins include hexon proteins (timers of hexon proteins pIIIa, pVI, pVIII 
and pIX), penton base proteins and fiber proteins along with a number of minor proteins 
that covers an inner nucleoprotein core (pV, pVI, mu and the histone like pVII proteins) 
[reviewed in (McConnell and Imperiale, 2004, Rosewell et al., 2011)]. The capsomeres 
form 12 capsid vertices, where each of the vertices have 5 hexon proteins that surround a 
penton base protein that serves as an anchor for fiber proteins. From each of the penton 
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base proteins, a fiber protein protrudes and aids in the binding of the vector to the host 
receptor [(Majhen and Ambriovic-Ristov, 2006, Reynolds and Curiel, 2002), Figure 1.2].  
 
 
 
Figure 1.2: Adenovirus particle structure 
Schematic presentation of the Adenovirus that is made up of 3 major proteins. The Fiber 
proteins, Pentose base and Hexon proteins, as well as the inner nucleoprotein core (Protein 
V and VII). The capsomeres form 12 capsid vertices where each of the vertices have 5 
hexon proteins that surround a penton base protein that serves as an anchor for fiber 
proteins. Adapted from (McConnell and Imperiale, 2004). 
 
The human Adenovirus has ~50 different serotypes and is classified into 6 groups (A-F). 
Of these serotypes, type 2 (Ad2) and type 5 (Ad5) of group C have been the most 
characterized and shown the best potential as recombinant adenoviral vector delivery 
systems for gene therapy [reviewed in (Kay et al., 2001, McConnell and Imperiale, 
2004)]. The Ad5 genome (Figure 1.3) is composed of 36 kb linear double stranded-DNA 
with cis-acting ITR's at both ends. It also has a 5' terminal protein (TP), which serves as a 
primer for viral replication initiation and a packaging signal (ψ) adjacent the left ITR (Liu 
et al., 2003, Majhen and Ambriovic-Ristov, 2006). Both the DNA strands serves as 
templates for transcription. The genome is divided in to three major transcription units 
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based mainly on the stage at which they are transcribed during viral replication. These are: 
the early transcription unit, mainly involved in early transcription activation, DNA 
replication and immune suppression (encoding E1A, E1B, E2, E3 and E4 transcripts); the 
delayed early transcription unit (encoding transcripts IX, IVa, VA RNA I and VA RNA II) 
mainly important for late transcription activation and capsid assembly; and late 
transcription unit encoding L1-L5 transcripts, from which the viral structural proteins are 
translated (Breyer et al., 2001). The E1 genes can be divided into the E1A and E1B 
transcription units. The E1A proteins regulate transcription and the S phase entrance of the 
host cells and the E1B aids in the transport of the viral mRNA and preventing the transport 
of the host mRNA. The E2A and E2B makes up the E2 region, where the DNA-binding 
protein is encoded by E2A and the viral polymerase and terminal protein precursor is 
encoded by the E2B region. The E3 region encodes for the proteins that provides the 
immunomodulatory functions. The remaining E4 region provides the proteins that are 
required for DNA replication, the reduction in host proteins synthesis and the 
enhancement of late gene expression. The late genes (L1-L5) are transcribed from a single 
promoter known as the major late promoter (MPL), to form one pre-mRNA, which is later 
processed by alternative splicing to produce multiple mRNAs. These late mRNAs encode 
for the structural Hexon, Pentose and Fiber proteins required for assembly of the viral 
particle [Reviewed in (McConnell and Imperiale, 2004, Vetrini and Ng, 2010)]. 
 
Adenoviruses uses a two stage process to infect the host cells. The efficiency of host cell 
infection by Ads is dependent on the binding and entry, which in turn is dependent on the 
primary and secondary receptors present on the host cell surface. The first stage entails the 
Ad fiber protein binding to the most commonly used Coxsackie-adenovirus receptor 
(CAR) on the cell surface. This is then followed by the initiation of receptor-mediated 
endocytosis that occurs through the clathrin-coated pits. Endocytosis is activated by the 
interaction between the arginine-glycine-aspartic acid (RGD) motif found on the pentose 
base of the Ad virion and the host cell surface integrins (αvβ3 and αvβ5). After the host 
cell entry by Ads and prior to lysosome formation, the virion escapes into the cytosol from 
the early endosome. The virion is then disassembled during trafficking through the 
microtubule network towards the nucleus, where the virion then binds to the nuclear pore 
complex (NPC) allowing for the release of the viral genome (DNA) into the nucleus. Once 
the viral DNA is within the nucleus, viral transcription process is initiated.
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Figure 1.3: Map of Adenoviral genome 5 and transcription units. 
Ad 5 genome is a linear double stranded DNA genome of 36 kb in size, with inverted terminal repeats (ITR) represented by the orange boxes on 
each end and the Ψ indicating the position of the packaging signal. The genome is divided into the early transcription unit (E1-E4), the late 
transcription unit (L1-L5) that is expressed from a major late promoter (MLP) and the delayed early transcription unit encoding proteins IX 
(pIX), pIVa, as well as VA RNA I and II. Adapted from (McConnell and Imperiale, 2004, Rosewell et al., 2011). 
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The viral DNA replication begins 6-8 hours post-infection, followed by the formation of 
progeny virion. The life cycle occurs within 24-36 hours and can produce 104 viral 
particles per infected cell [reviewed in (McConnell and Imperiale, 2004, Vetrini and Ng, 
2010, Reynolds and Curiel, 2002)].  
 
Prior studies showed that recombinant adenoviruses could be used to deliver anti-HBV 
sequences in vivo, but with a short duration of transgene expression. The use of these 
vectors has been limited by the immune stimulation that induces an innate and adaptive 
immune response (Crowther et al., 2008, Crowther et al., 2014, Zhao et al., 2008). 
However, progress has been made to increase the duration of the transgene expression and 
to make Ad safer and more efficient. This was achieved by the deletion of multiple 
adenovirus genes, which also allow the insertion of transgenes, resulting in three 
generations of Ad vectors: first generation, second generation and third generation Helper 
Dependent Adenoviral vectors (Ehrhardt and Kay, 2002). 
 
1.3.1.3.1 First and second generation vectors 
 
First generation adenoviral vectors (FGAd) have been constructed by the substitution of 
the E1 region of the Ad5 with a transgene (Figure 1.4). Hence, FGAd are E1 region (early 
region) deficient, which is required for the stimulation of the viral gene expression. The 
removal of this region results in a replication impaired vector with impaired early and late 
gene expression. E1 deficient Ad vectors propagation is performed in a HEK293 cell line 
(human embryonic kidney derived) that express E1 genes of Ad to provide the E1 function 
in trans (Amalfitano et al., 1998, Imperiale et al., 1984, Morral et al., 1997). Despite the 
removal of E1, expression of the viral genes is not completely blocked, resulting in the 
continuing expression of remaining viral genes. In turn, the viral gene expression results in 
the stimulation of the immune response (Holkers et al., 2014, Graham, 2000). 
Furthermore, another shortcoming associated with FGAd, is the short-term (3 weeks – 5 
weeks) transgene expression after administration. Studies have suggested that the short-
term transgene expression is due to the activation of the cellular immune response, 
specifically the CD8+ T lymphocytes activation by viral proteins (Holkers et al., 2014, 
Morral et al., 1997).  
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These shortcomings have prompted the development and construction of second 
generation vectors by further deletion of genes E2 and E4. In addition, the E3 region can 
also be removed allowing up to 8.2 kb space for insertion of foreign DNA or gene (Figure 
1.4). The E3 region can be removed due to the non-essential function that the E3 region 
has in viral production and growth during in vitro culturing (Amalfitano et al., 1998, 
Morral et al., 1997, Ilan et al., 1997). This produces less immunogenic vectors and 
increases the transgene capacity. However, viral gene expression still occurs and an 
immune response against vira1 proteins persists, which lead to the destruction or clearance 
of the transgene expressing vectors (Ehrhardt and Kay, 2002). 
 
 
 
Figure 1.4: Genome structure of First-, Second- and Helper dependent Adenoviral 
vectors.  
Adenoviral vector genome organization of First-, Second- and Third generation Helper 
Dependent Ad vectors (HDAd) with the inverted terminal repeats (ITR) represented by the 
orange boxes and the Ψ indicates the position of the packaging signal. The white boxes 
indicated the Ad genes that have been deleted to generate the different Ad vectors, the 
transgene (yellow box) has replaced the ΔE1 region in first- and second Ad vectors, 
HDAd vector yellow box indicates site of transgene insert. Adapted from (McConnell and 
Imperiale, 2004). 
 
1.3.1.3.2 Helper-dependent Adenoviral vectors 
 
To avoid the liver toxicity and the immune stimulation associated with the early 
generations of Adenoviral vectors, Helper Dependent Adenoviral vectors (HDAd) have 
been constructed. All the viral-coding genes are deleted in HDAds, thereby supporting a 
large cloning capacity that can accommodate transgene sequences of up to 37 kb. 
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Consequently, leaving only the two ITRs required for replication and the packaging signal 
(Figure 1.4) that is necessary for encapsidation of the viral genome (Brunetti-Pierri et al., 
2006, Croyle et al., 2005, Ng et al., 2002). As a result of the removal of all the viral genes 
and the fact that expression of all the required adenoviral genes in a cell line is toxic, a 
helper virus (HV) is used to aid in the propagation of HDAds. The HV used should be able 
to express all the viral proteins required for the packaging and propagation of the HDAd 
genome. However, for a pure HDAd to be produced, the packaging of HV genome needs 
to be inhibited [reviewed in (McConnell and Imperiale, 2004, Rosewell et al., 2011)].  
 
Previous techniques used a HV with a mutated packaging signal and an HDAd vector that 
is smaller in size compared to the HV. The size difference was used with the hope to 
minimize the HV contamination by separating the two viral particles based on size and 
density. However, the HDAd preparation remained contaminated with substantial levels of 
HV after the purification stage. The unresolved HV contamination issue was approached 
by the Cre/loxP technique that was engineered by Graham, Parks and co-workers (Parks et 
al., 1996, Parks and Graham, 1997). This strategy has shown to be most efficient and 
widely used for the large production of HDAd according to the production method 
developed by Palmer and Ng (Palmer and Ng, 2011).  
 
1.3.1.3.2.1 Cre/loxP system for HDAd production and propagation 
 
Cre/loxP system (Figure 1.5) makes use of HEK293 kidney derived cells that expresses 
Cre recombinase (Cre protein, 116 cells). These 116 cells are transfected with the 
linearized HDAd genome bearing plasmid and infected with a helper virus (HV) that is an 
FGAd that bears loxP sites flanking the packaging signal (AdNG163). In the presence of 
Cre recombinase the HV packaging signal is excised through site-specific recombination 
between the direct repeats of loxP, thereby rendering the HV genome unpackageable. This 
allows for selective replication and packaging of the HDAd genomes. However, the HV 
still retains its functional abilities to complement in trans for the adenoviral genes required 
for replication and packaging of the HDAd genome in trans (Ng et al., 2002, Parks et al., 
1999, Parks et al., 1996, Parks and Graham, 1997).  
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Figure 1.5: Cre/loxP Helper dependent viral production system.  
HDAd genome is released through Pme I restriction digest from HDAd genome bearing plasmid. The HDAd genome is made up of cis-acting 
sequences, with ITRs and packaging signal (Ψ), the promoter driving the transgene expression, with the remainder stuffer DNA. The HDAd
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genome is transfected into Cre expressing HEK293 cells. Cells are infected with helper 
virus with a packaging signal flanked by loxP sites. Cre expression renders the helper 
virus unpackagable, but still provides the factors necessary for HDAd propagation. 
Adapted from (Palmer and Ng, 2008b). 
 
1.3.1.3.2.2 HDAd for liver directed gene therapy and HBV treatment  
 
Adenoviruses have a tropism for a wide range of tissues, but are highly efficient 
hepatotropic vectors. Majority of in vivo liver directed studies have been performed with 
Ads as delivery vectors. Numerous studies have shown the potential use of Helper 
Dependent Adenoviral vectors for liver directed gene therapy in the absence of chronic 
toxicity with long-term transgene expression in both mice and non-human primates after 
systemic administration. Liver directed HDAd vectors were constructed that expresses the 
human α-1-antitrypsin (hAAT) gene that was administered to three baboons. Sustained 
transgene expression was obtained for more than one year with insignificant liver toxicity 
(Morral et al., 1999).  
 
Further studies performed by Kim and colleagues (Kim et al., 2001) with Apolipoprotein 
E (apoE) HDAd vectors showed a stable, long-term and high transgene expression of apoE 
after a single intravenous administration. The high apoE expression resulted in complete 
long-term (2-2.5 years, mice died of natural causes) correction of hypercholesterolemia in 
apoE deficient mice (Kim et al., 2001).  
 
HBVs ability to infect almost 100 % of liver hepatocytes, prompted the use of Ad vectors 
as a viable treatment for HBV. The durable transgene expression observed with using 
HDAd vectors, made these vectors appropriate for the treatment of chronic viral infections 
such as HBV (Mowa et al., 2012, Mowa et al., 2014, Ng et al., 2002). Numerous studies 
have shown the use of HDAd in liver directed gene therapy for HBV treatment both in 
vitro and in vivo (Crowther et al., 2008, Crowther et al., 2014, Mowa et al., 2012, Mowa 
et al., 2014, Ng et al., 2002). Different approaches for HBV treatment were investigated, 
one of these approaches focuses on immunotherapy treatments that are based on IFN-α 
antiviral ability to suppress hepadnavirus replication. Efficient reduction in the replication 
of Woodchuck Hepatitis virus (WHV) had been demonstrated using HDAd vectors (HD-
AdwIFN) that express Woodchuck cytokine interferon (IFN) cytokines. As a result, the 
development of hepadnavirus infection into chronic infection and HCC could be 
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prevented (Fiedler et al., 2004). Aurisicchio and colleagues further investigated the utility 
of IFN expressing HDAd vectors in transgenic mice. HDAd vectors expressing murine 
specific IFN-α (mIFNa2) from a liver specific transthyretin promoter were constructed. 
These HDAd vectors resulted in an antiviral intrahepatic IFN-α expression, which 
produced a higher degree of liver protection in mice with acute hepatitis compared to 
FGAd (Aurisicchio et al., 2000).  Both these studies present liver-restricted expression of 
IFN as being a potential gene therapy treatment for chronic hepatitis. 
 
A different approach for HDAd based HBV treatment is the application of RNAi-based 
therapy. One of the first studies using HDAd vectors expressing shRNA from U6 
promoter against HBV was performed.  However, a modest level of HBV replication 
inhibition in the transgenic HBV mouse model was demonstrated (Rauschhuber et al., 
2008). The inadequate level of HBV replication inhibition is speculated to be due to lack 
of potent silencing by the designed anti-HBV shRNA. Hence, the design of the anti-HBV 
sequences is of great importance to achieve potent and efficient HBV replication silencing. 
Another study performed addressed the use of the HDAd vectors expressing anti-HBV 
shRNA that target the HBx sequence. During this study the HDAd shRNA transduced 80-
90 % of hepatocytes and generated the desired HBV targeted guides successfully. As a 
result, 95 % of HBV replication was inhibited with sustained HBV silencing of up to 8 
weeks (Crowther et al., 2014).  
 
However, to further improve the safety, sustainability and efficiency of HBV silencing, 
recombinant HDAds expressing previously designed artificial anti-HBV pri-miRs (Ely et 
al., 2009, Ely et al., 2008) were generated within the Antiviral Gene Therapy Research 
Unit. Mowa and colleagues performed one of the first experimental studies using this 
approach by constructing anti-HBV HDAds expressing pri-miR from a cytomegalovirus 
(CMV) promoter. These vectors transduced 90 % of hepatocytes and inhibited HBV 
replication efficiently in vivo without toxic side effects (Mowa et al., 2012). To advance 
this approach, further studies were conducted by Mowa and colleagues expressing both 
mono and trimeric anti-HBV pri-miRs in HDAds from a liver specific modified mouse 
transthyretin (MTTR) promoter.  It was demonstrated that the expression of these anti-
HBV pri-miRs by HDAd was more sustained (3 weeks for the monomeric pri-miR 
cassettes and after 5 weeks for the trimeric pri-miR cassettes) as compared to the CMV 
promoter driven pri-miRs and a significant inhibition of HBV replication in vivo was 
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achieved. Moreover, hepatotoxicity that have been found to occur with shRNA was not 
observed with antiviral pri-miR (Mowa et al., 2014). The results obtained showed the 
therapeutic potential and effective utility of HDAd for HBV gene silencing and 
hepatotropic delivery of antiviral sequences.  Nevertheless, one of the main obstacles that 
prevent HDAd as clinical application for liver-directed gene therapy is the triggering of 
the host innate inflammatory response against the capsid proteins and reporter genes that 
are usually carried by the vectors. However, efforts have been made in elucidating the 
factors triggering the host response and various strategies have been investigated to 
improve the therapeutic potential of HDAd (Brunetti-Pierri and Ng, 2011). 
 
1.3.1.4 Suppression of Ads immunostimulatory effects 
 
Despite the progress that has been made by manipulating the viral genome of the vectors, 
Ad vectors still have to overcome the host innate response that limits the efficient delivery 
and safe application of these vectors in vivo. This is as a result to the immune response 
that causes acute toxicity, as well as influence and limit transgene delivery and expression 
(Crowther et al., 2008, Crowther et al., 2014, Croyle et al., 2005).  
 
The host immune response caused by Ad vectors occurs in phases. Phase one, also known 
as acute phase follows 1 hour to 4 days post administration. The acute phase is associated 
with the activation of Kupffer cells present in the liver, as well as macrophages and 
dendritic cells found within the spleen and peritoneum. These cells produce and release 
numerous cytokines (IL-1, IL-6, TNF-α) and chemokines (MCP-1, MIP-1, IP-10) into 
circulation. The released chemokines and cytokines sets an acute innate inflammatory 
response and toxicity in progress. Phase two occurs 5-7 days post administration and 
targets Ad viral particle transduced cells. This entails the activation of major 
histocompatibility complex (MHC) class I and II that is specific for Adenovirus and 
results in the production of anti-adenovirus neutralizing antibodies. MHC class I CD8+ T 
cells are directed towards the transgene products and cells expressing the viral genes. 
MHC class II CD4+ T cells are activated by the viral particles capsid proteins. As a result, 
rapid Ad viral clearance from the blood circulation occurs, influencing the hepatocyte 
transduction efficiency and preventing transgene expression (Lieber et al., 1997, Muruve 
et al., 1999, Schiedner et al., 2003, Zhang et al., 2001). Phase two is followed by the 
chronic host immune response (late phase) that continues for several weeks to months post 
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administration. During this time all transgene products and transduced cells are eliminated 
by cytotoxic T cells (Croyle et al., 2005, Yang et al., 1996, Yang et al., 1995).  
 
First generation adenoviral (FGAd) vectors have fallen short as an ideal gene delivery 
vectors due to the activation of the innate immune response and toxicity following 
administration. Consequently, HDAd vectors were generated to minimize the immune 
response and toxicity that have been associated with FGAd vectors by the removal of the 
ORFs (all viral genes), this reduces long-term humoral and cell-mediate adaptive 
immunity (Crowther et al., 2008, Crowther et al., 2014, McCaffrey et al., 2008, Muruve et 
al., 2004). However, the formation of Ad specific neutralising antibodies generated against 
the Adenoviral capsid proteins limits transgene expression and prevents the re-
administration of the same Ad serotype (O'Riordan et al., 1999, Yang et al., 1995). Given 
the initiation of the host response by the capsid proteins, methods have been developed to 
diminish the host innate response by modifying the capsid proteins of Ad vectors using 
polymers such as polyethylene glycol (PEG), PEG derivatives and poly-N-(2-
hydroxypropyl) methacrylamide (Croyle et al., 2001, Kreppel et al., 2005, Mok et al., 
2005, Eto et al., 2004, Prill et al., 2011, Croyle et al., 2005). 
 
1.3.1.4.1 PEGylation of delivery vectors 
 
PEGylation has been introduced by pharmaceutical companies since the 1970s to protect a 
variety of therapeutic proteins and transgenes. This method decreases the non-specific 
uptake by macrophages while maintaining the uptake of Ad vectors into target cells in vivo 
(Mok et al., 2005, Croyle et al., 2001, Kreppel et al., 2005). PEG is an uncharged, non-
immunogenic and hydrophillic molecule with low toxicity and reduces the protein-protein 
interaction that occurs between proteins, therapeutics and cells. The chemical modification 
is achieved through the covalent attachment between Adenovirus vector and PEG that 
forms a hydrophillic coat. Attachment of PEG to lysine’s amine residues that are present 
on the Ad capsid has been the most commonly used method of PEGylation. Previous 
studies have shown that PEG protects the viral particles against neutralizing antibodies. 
This increased viral particle circulation time, decreased the blood clearance of PEG-FGAd 
and -HDAd vectors by 2-5 fold and demonstrated a reduction in cytotoxicity and helper T 
lymphocyte innate immune response (Croyle et al., 2005, Eto et al., 2008, Kreppel and 
Kochanek, 2008, Hofherr et al., 2008, Mok et al., 2005, Croyle et al., 2000). These 
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promising results prompted the use of PEGylated Ad vectors for HBV treatment. During 
recent studies performed by Crowther and colleagues, FGAd and HDAd vector surface 
chemical modification was performed using amine reactive PEG. The anti-HBV FGAd 
and -HDAd PEGylated vectors were shown to improve hepatocyte transduction and 
silencing of HBV replication in HBV transgenic mice (Crowther et al., 2008, Crowther et 
al., 2014).  
 
However, evidence have also shown that using amine reactive PEG is non-specific and 
can interfere with the vector particles intracellular trafficking to targeted tissue (Croyle et 
al., 2005, Hofherr et al., 2008). Hence, a more effective approach was investigated by 
applying genetic and chemical capsid modification. The genetic technique is used to 
introduce a specific genetic mutation by the substitution or addition of desired amino acids 
in the capsid proteins. This introduced a specific chemical reactivity with a specific PEG 
at a desired site on the viral capsids. The use of site-specific PEGylation has found to 
reduce the attachment of PEG to undesired protein surface, reduce biological activity loss, 
as well as minimized the amount of PEG conjugates required for masking the desired 
capsid epitopes (Kreppel et al., 2005, Prill et al., 2011). Prill and colleagues applied this 
method to improve the delivery of Adenoviral vectors to the liver by using thiol reactive 
PEG, which reacts with thiol groups in cysteine residues that was introduced into the 
hypervariable region 5 (HVR 5) of the hexon protein (Figure 1.6). This was done by 
generating a helper virus (E1 deficient Ad vector); AdNG163Cys with same ratio of 
Amide (A) to Cysteine (C) mutations into the hexons hypervariable region 5 (HVR 5) of 
AdNG163 helper virus. This approach showed an increase in hepatocyte transduction, 
higher particle uniformity by allowing precise shielding at the desired sites, and a 
reduction in the amount of polymers required. Furthermore, this strategy also showed that 
the introduction of a specific point mutation at a single site of a hexon protein can alter 
hepatocyte tropism by either reducing or increasing hepatocyte transduction depending on 
the chemical moieties that covalently binds to the genetically modified hexon (Prill et al., 
2011). A similar approach was applied whereby peptides with cysteine residues were 
genetically introduced into a solvent-exposed fiber protein H1-loop of Ad5 E1 deleted 
Adenovirus vector. This genetic introduction enable the detargeting and retargeting of 
Adenoviral vectors to specific tissue sites (Kreppel et al., 2005). 
CHAPTER 1  MSc Dissertation 2017 
25 | P a g e  
 
 
 
 
 
Figure 1.6: Chemical modification of adenovirus capsid proteins. 
Chemical modification of the genetically introduced cysteine residues in the HVR5 of 
hexon, with thiol-reactive maleimide-activated PEG molecules. , indicates the reaction 
between maleimide and thiol groups. Adapted from (Prill et al., 2011, Kreppel and 
Kochanek, 2008). 
 
1.3.1.4.2 Immune stimulation by transgene products 
 
In addition to the capsid specific immune stimulation, other studies reported that reporter 
gene products can activate an immune response. Lac Z is a reporter gene that encodes E. 
coli β-galactosidase and has mainly been used for the visualization and detection of cells 
infected with vectors carrying the desired transgenes (Mian et al., 2005, Sullivan et al., 
1997). The presence of β-galactosidase in cells can be recognized by the catalyses of X-gal 
(5-bromo-4-chloro-3-indoyl-b-D-galactopyranoside) substrate,  to produce a blue colour 
(Juers et al., 2012). However, despite the great use of lac Z as a model gene marker in 
both animal and human pre-clinical studies, an induction of a host immune response by β-
galactosidase has been observed. A loss in viral gene expression is observed as a result of 
the stimulation of the adaptive immune response and/or cellular immune response that is 
characterized by CD4+ and CD8+ cytotoxic T lymphocytes which results in the destruction 
of transduced cells (Mian et al., 2005, Morral et al., 1997). Studies performed indicated 
the induction of the inflammatory response (CD4+ and CD8+ cell) by the expression of β-
galactosidase in non-transgenic mice (Chen et al., 1997). Further studies performed by 
Sullivan and colleagues showed the activation of an immune response that induced antigen 
T-cell proliferation and neutralising antibody production against the β-galactosidase 
expressed in Adenoviral vectors (Sullivan et al., 1997). Experimental studies performed 
within AGTRU used the lac Z reporter gene to enable visualization of cells infected with 
shRNA or pri-miR expressing HDAd vectors respectively. An activation of the adaptive 
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immune response of the host was observed through the increased antibody production 
against β-galactosidase using ELISA and ELISpot assays (Crowther et al., 2014, Mowa et 
al., 2014). Although the use of a reporter gene is convenient for the detection of in vivo 
hepatocyte infection, viral vector clearance and short-term HBV gene silencing was 
observed. 
 
Hence, this study focused on liver specific expression and HBV silencing by using anti-
HBV HDAd vectors lacking lac Z, making them more efficient and more relevant for 
chronic HBV infection treatment. The elimination of the lac Z cassette of the vectors may 
rid the system of short-term HBV replication inhibition problem. On the other hand, 
incorporation of the PEPCK promoter in anti-HBV HDAds lacking the lac Z gene may aid 
in prolonged HBV gene silencing. 
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1.4 Aim and objectives 
 
This study focuses on finding efficient, tissue specific expression and a safer delivery 
system for anti-HBV RNAi activators. The specific aim of this study therefore was to 
produce recombinant HDAd that are lac Z deficient and express anti-HBV pri-miR 
sequences from a PEPCK liver-specific promoter. To achieve this aim, the following 
objectives were set: 
 
Objectives: 
1. Construction of recombinant Helper Dependent Adenoviral vector (HDAd) 
backbones expressing anti-HBV sequences from a liver-specific PEPCK promoter 
(pPEPCKHBVHDAds).  
2. Production and propagation of anti-HBV recombinant Helper Dependent 
Adenoviral vectors (HBVHDAds) using a helper virus with or without cysteine 
modification in the Hypervariable region. 
3. Validation of PEPCK promoter liver specific activity by producing HDAd 
expressing Firefly luciferase and characterization in vitro and in vivo. 
4. Assessment of in vitro and in vivo expression and processing of anti-HBV 
sequences using Northern blotting. 
5. Assessment of silencing of HBV gene expression in cell culture and mice using 
Dual Luciferase reporter assay and/or ELISA. 
6. Determination of immune stimulation by anti-HBV Helper Dependent Adenoviral 
vectors using cytometric bead array. 
7. Measurement of liver enzymes levels as markers of liver toxicity using kinetic 
assay on an automated photomeric analyser. 
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CHAPTER 2 
 
2 MATERIAL AND METHODS 
 
2.1 Bacterial culturing and manipulations 
 
2.1.1 Culturing of Escherichia coli strains 
 
XL1-Blue and DH5-α E. coli strains were cultured in Luria Bertani medium (LB, 
Appendix 6.1) or grown on Luria Bertani agar plates (LA, Appendix 6.1) at 37 ̊C 
overnight. The XL1-Blue strains carrying ampicillin resistance marker were cultured in 
LB or LA supplemented with 100 µg/ml ampicillin (Appendix 6.1). The DH5α strains that 
are kanamycin resistant were cultured in LB or LA supplemented with 50 µg/ml 
kanamycin (Appendix 6.1). Blue white screening was performed by evenly spreading 40 
µl of 20 mg/ml X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) (Appendix 
6.1) on LA plates containing the relevant antibiotic. All liquid bacterial cultures were 
shaken at 150 - 250 rpm.  
 
2.1.2 Preparation of chemically competent XL1-Blue E. coli cells 
 
A single colony or 5 µl of freezer stock XL1-Blue cells were inoculated in 10 ml LB. The 
cultures were incubated overnight at 37 ̊C shaking at 150-250 rpm. The pre-cultures were 
diluted 100 × in 100 ml of LB medium and incubated at 37 ̊C shaking at 150 - 250 rpm 
until the absorbance reading (optical density, OD) measured 0.4 - 0.6 at 600 nm. The 
cultures were then centrifuged at 2500 rpm for 20 min at 4 C̊. The pellets were 
resuspended in 20 ml of transformation buffer (Appendix 6.1) and incubated on ice for 20 
- 30 minutes. The cells were centrifuged at 2500 rpm for 20 minutes at 4 ̊C and 
resuspended in 1 ml of transformation buffer (Appendix 6.1). Aliquots were made by 
transferring 100 µl of competent cells in to sterile microcentrifuge tubes and stored at -
80 C̊. 
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2.1.3 Transformation of E. coli competent cells 
 
2.1.3.1 Transformation of chemically competent XL1-Blue E. coli cells by heat 
shock 
 
Pre-chilled DNA was added to 100 µl of competent cells. The mixture was incubated on 
ice for 10 minutes followed by heat shock at 42 ̊C for 90 seconds using a heating block. 
Immediately after heat shock, 500 µl of LB pre-warmed at 37 ̊C was added to the cells and 
incubated for an hour at 37 ̊C to allow selection marker expression. The whole 
transformation mixture was then plated onto LA media containing X-gal and/or the 
relevant antibiotic and incubated overnight at 37 ̊C. 
 
2.1.3.2 Electroporation of DH5-Alpha E. coli cells 
 
DNA was added to 50 µl of commercially obtained DH5-Alpha electro-competent cells 
(New England Biolabs, Inqaba Biotec, Gauteng, South Africa) and incubated on ice for 10 
minutes. After incubation, the mixtures were transferred to a pre-chilled 2 mm 
electroporation cuvettes. Cells were then electroporated using the Biorad Gene Pulsar 
XcellTM Electroporation system under the following conditions: 2000 V (voltage), 25 µF 
(capacitance) and 200 Ω (resistance). Immediately after electroporation, 1 ml of rescue C-
medium (Thermo Fisher Scientific, MA, USA) pre-warmed at 37 ̊C was added to the cells. 
Cells were then transferred into a sterile microcentrifuge tube and incubated at 37 ̊C 
shaking at 150 - 250 rpm for 1 hour for phenotypic expression. After incubation, the 
transformed cells were plated onto LA plates supplemented with desired antibiotic and 
incubated overnight at 37 ̊C. 
 
2.2 Isolation and purification of DNA 
 
2.2.1 Small Scale plasmid DNA isolation by alkaline lysis (mini prep) 
 
A single colony was inoculated into 1 ml of LB supplemented with the relevant antibiotic 
and incubated overnight in a 37 ̊C incubator shaking at 150 - 250 rpm. The bacterial 
cultures were transferred to 1 ml microcentrifuge tubes. The cultures were centrifuged for 
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1 min at maximum speed at room temperature. The pellets were resuspended in 180 µl of 
Buffer P1 with RNase A (resuspension buffer, Appendix 6.2). The cells were then lysed 
by adding 160 µl of Buffer P2 (lysis buffer, Appendix 6.2). The solution was mixed 
thoroughly by inverting and incubated at room temperature for 5 minutes. After 
incubation, 120 µl of Buffer P3 (neutralization buffer, Appendix 6.2) was added to the 
solution and mixed thoroughly by flicking. The solution was incubated on ice for 5 
minutes. The bacterial lysate was then centrifuged at maximum speed for 15 minutes at 
4 ̊C. The supernatant was transferred to a new sterile tube to which 600 µl of warm 100 % 
isopropanol was added to precipitate the plasmid DNA. The mixture was mixed by 
inverting and incubated at room temperature for 2 minutes, followed by centrifugation at 
maximum speed for 25 minutes at room temperature. The supernatant was discarded and 
the pellet was washed with 150 µl of chilled 70 % ethanol through centrifugation at 
maximum speed for 5 minutes at 4 ̊C. The supernatant was carefully removed as 
completely as possible and the pellet was left to air-dry for 10 minutes. The DNA was re-
dissolved in 50 μl of distilled water and incubated at room temperature for 30 minutes. 
The DNA concentration was determined using Nanodrop® Spectrophotometer (Thermo 
Fisher Scientific, MA, USA).  
 
2.2.2 Large scale plasmid DNA isolation (maxi prep) 
 
Plasmid DNA required in large quantities were isolated using QIAGEN Plasmid Maxi Kit 
(Qiagen, MD, USA) or Genopure Plasmid Maxi Kit (Roche Holding AG, South Africa) 
according to the manufacturer’s instructions with minor changes. Briefly, a single colony 
was inoculated in 100 - 200 ml of LB medium supplemented with the appropriate 
antibiotic and incubated overnight at 37 ̊C, shaking at 150 rpm. The bacterial cells were 
harvested by centrifugation at 4000 rpm for 30 minutes at 4 ̊C. The pellets were 
resuspended in 12 - 20 ml of chilled resuspension buffer with RNase A. To lyse the cells, 
12 - 20 ml of lysis buffer was subsequently added and mixed by inverting the tube 6 - 8 
times. The mixture was incubated at room temperature for 5 minutes. To neutralize the 
lysis buffer, 12 - 20 ml of chilled neutralising buffer was added and the samples were 
mixed by inverting 6 - 8 times and incubated on ice for 5 - 20 minutes. The lysates were 
cleared by centrifugation at 4000 rpm for 1 hour at 4 ̊C. During centrifugation step, the 
columns were mounted onto a collection tube and equilibrated by applying 12 - 20 ml of 
equilibration buffer and allowed to empty by gravity flow. Each column had a filter paper 
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to which the cleared lysate was loaded and allowed to flow through and enter the resin by 
gravity flow, followed by washing twice with 16 - 30 ml of wash buffer. The columns 
were transferred to new collection tubes and the plasmid DNA was eluted with 15 ml of 
Elution buffer. The DNA was precipitated by adding 10.5 - 11 ml of room temperature 
isopropanol. The precipitated solution was mixed and incubated at -20 ̊C for 30 minutes. 
The plasmid DNA was collected by centrifugation at 4000 rpm for 45 minutes at 4 ̊C. The 
supernatant was carefully discarded, the pellet was washed with 4 - 5 ml of chilled 70 % 
ethanol and centrifuged at 4000 rpm for 10 minutes at 4 C̊. The ethanol was carefully 
discarded and the pellets were air-dried for 10 minutes. The plasmid DNA pellet was re-
dissolved in 500 µl of sterile distilled water (dH2O). DNA concentration was determined 
by using the Nanodrop® Spectrophotometer (Thermo Fisher Scientific, MA, USA).  
 
2.2.3 Viral DNA isolation and purification 
 
Viral DNA was isolated using the QIAamp DNA Mini Kit (Qiagen, MD, USA) according 
to the manufacturer’s instructions. All centrifugation steps were carried out at room 
temperature. For tissue lysis, 200 µl of homogenates and tissue lysis buffer (ATL) were 
added into a 1.5 ml micro-centrifuge tube containing 20 µl of Proteinase K and incubated 
at 56 ̊C until tissue was completely lysed (1 - 3 hours). For viral lysis a total of 200 µl of 
sample was added to the tube containing 200 µl of buffer AL and mixed my vortexing for 
15 seconds. Samples were incubated at 56 ̊C or 70 ̊C for 10 minutes, followed by a brief 
centrifugation. Absolute ethanol (200 µl) was added to the samples, mixed by vortexing 
for 15 seconds and briefly centrifuged. The samples were then applied to the QIAamp 
mini spin columns and centrifuged at 8000 rpm for 1 minute. The spin columns were 
transferred to new 2 ml collection tubes, 500 µl of Buffer AW1 was added and centrifuged 
at 8000 rpm for 1 minute. The columns were transferred to new 2 ml collection tubes, 500 
µl of Buffer AW2 was added and centrifuged at maximum speed for 3 minutes. The 
columns were again transferred into new collection tubes and centrifuged at maximum 
speed for 1 minute and then transferred into a new 1.5 ml micro centrifuge tubes. To elute 
the DNA, 50 - 200 µl of Buffer AE was added and incubated at room temperature for 1 
min. The columns were then centrifuged at 8000 rpm’s for 1 minute. For tissue samples 
the final elution and centrifugation step was repeated. 
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2.2.4 DNA analysis and purification by agarose gel electrophoresis 
 
A 1 % agarose gel was prepared by adding 1 g of powdered agarose to 100 ml 1× TAE 
(Tris-Acetate-EDTA, Appendix 6.2) running buffer and mixed by swirling. The mixture 
was melted in the microwave for 3 minutes. Distilled water was used to adjust the volume 
to 100 ml after heating to compensate for the evaporated water. The agarose was left to 
cool and 10 µl of 10 mg/ml Ethidium bromide (Sigma-Aldrich, MO, USA) was added to 
the melted agarose to enable visualisation of DNA. The gel was poured into the casting 
tray and allowed to solidify at room temperature. Orange DNA loading dye (1×, Thermo 
Fisher Scientific, MA, USA) was added to the samples and loaded into the gel wells. The 
O’ GeneRuler DNA Ladder Mix (Thermo Fisher Scientific, MA, USA) was added to a 
well alongside the samples to determine the relative size of the fragments. The samples 
were separated through electrophoresis at 100 V. The agarose gel was visualised under 
UV light and pictures were taken using the Syngene G:BOX Gel Documentation and 
Analysis system (Syngene, UK).  
 
To purify DNA from the gel, a DNA fragment of interest was excised from the gel using a 
sharp, clean scalpel. The extraction of the DNA was further completed using QIAquick 
Gel Extraction Kit (Quigen, MD, USA) according to manufacturer’s instructions. All 
centrifugation steps were performed at room temperature. The excised gel piece was 
transferred into a 2 ml eppendorf tube and weighed. Three volumes of buffer QG was 
added to 1 volume of gel (0.1g ~ 100 µl) and incubated at 50 ̊C, vortexing the tube every 2 
- 3 minutes. Once the gel slice was entirely dissolved, one volume of isopropanol (0.1g ~ 
100 µl) was added to the sample and mixed by inverting. The QIAquick spin column was 
placed into the provided 2 ml collection tube. The sample was applied to the column to 
bind the DNA and centrifuged for 1 minute at maximum speed. The flow through was 
discarded and column was placed back into the collection tube. The binding of DNA was 
continued until all the sample had been applied to the spin column. To remove all traces of 
agarose, 500 µl of Buffer QG was applied to the spin column and centrifuged for 1 minute. 
Flow through was discarded. To wash, 750 µl of Buffer PE was added to the spin column 
and centrifuged for 1 minute. The residual ethanol from Buffer PE was removed by 
discarding the flow through and centrifuging the QIAquick spin column for 1 minute at 
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maximum speed and transferred into a clean 1.5 ml eppendorf tube. The DNA was eluted 
by adding 30 µl of sterile distilled water (dH2O) and incubating at room temperature for 1 
minute. The column was then centrifuged at maximum speed for 1 minute. To ensure 
maximum elution of DNA, the eluted sample was added back to the column and 
centrifuged at maximum speed for 1 minute. The DNA concentration was determined 
using the Nanodrop® Spectrophotometer. 
 
2.3. DNA manipulations 
 
2.3.1 Restriction digestion of plasmid DNA  
 
The restriction digest reactions were carried out according to the manufacturer’s 
instructions in recommended restriction buffer (Thermo Fisher Scientific, MA, USA or 
New England Biolabs, MA, USA). Briefly, 1-11 µg of DNA, 1-11 U of enzyme and 1× 
reaction buffer was added into a 1.5 ml Eppendorf tube and distilled water was used to 
scale up the reaction to the required volume of 10 - 50 µl. The restriction digests were 
performed at 37 ̊C for 2 hours to overnight. 
 
2.3.2 Plasmid DNA dephosphorylation 
 
Plasmid dephosphorylation was performed to prevent the religation of the linearised 
plasmid by removing the 5’ phosphate groups at the ends of the plasmid. A total of 1 - 5 U 
Antarctic Phosphatase (New England Biolabs, MA, USA) was added to 1 - 5 µg of 
linearised DNA in a 1× restriction buffer. The reactions were incubated at 37 ̊C for 1 hour 
and heat inactivated at 65 ̊C for 5 minutes.  
 
2.3.3 Polymerase Chain Reaction (PCR) 
 
KAPA HiFi HotStart ReadyMix kit (KAPA Biosystems, Cape Town, South Africa), 
KAPA Taq Polymerase ReadyMix PCR kit (KAPA Biosystems, Cape Town, South 
Africa) or Thermo Scientific High Fidelity PCR kit (Thermo Scientific, MA, USA) were 
used for DNA amplifications according to manufacturer’s instructions. Each KAPA 
reaction contained 5-10 ng of template DNA, 0.2 - 0.4 µM of forward and reverse primer, 
1 ×  KAPA HiFi HotStart ReadyMix (containing 2.5 mM Mg3+) or 1 × KAPA Taq 
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ReadyMix (containing 1.5 mM MgCl2) and PCR grade (nuclease free) water to a final 
volume of 25 - 50 µl. For colony PCR, a single colony was suspended in 10 µl of dH2O, 
and 1 µl per reaction used as the template. The reaction for Thermo Scientific High 
Fidelity PCR kit was set up with 1× High Fidelity PCR buffer with 15 mM MgCl2, 0.2 
mM dNTP mix, 1 µM forward and reverse primer, 5 ng of template DNA, 12.5 - 25 µl 2× 
High Fidelity PCR enzyme mix and nuclease free water up to a final volume of 50 µl. 
Primers used are shown in Table 2.1 and PCR cycling conditions were as outlined in Table 
2.2. 
 
Table 2.1: Oligonucleotides (primers) used for amplification during PCR and qPCR 
Primer Name Primer sequence Description 
Source/ 
Reference 
EcoRVF 
5’GATCGATATCC
AGGTGTCCACTCC
CAGTTC3’ 
Forward primer with 
engineered EcoRV sites used 
for Firefly luciferase sequence 
amplification 
Unpublished 
EcoRVR 
5’GATCGATATCC
CTCACTAAAGGG
AAGCGGC3’ 
Reverse primer with 
engineered EcoRV sites used 
for Firefly luciferase sequence 
amplification 
Helper Virus 
F (HVF) 
5’TGGGCGTGGTG
CCTAAAA’3 
Forward primer specific for 
HV amplification (Palmer and 
Ng, 2003) Helper Virus 
R (HVR) 
5’GCCTGCCCCTGG
CAAT’3 
Reverse primer specific for HV 
amplification 
HDAdF 
5’GAAAAAACACA
CTGGCTTGAAACA
’3 
Forward primers specific for 
HDAd amplification (Palmer and 
Ng, 2003) 
HDAdR 
5’TGCCACCTCGTA
TTTCACCTCTA’3 
Reverse primer specific for 
HDAd amplification 
The Eco RV restriction sites indicated in blue.  
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Table 2.2: PCR cycling conditions 
Step Temperature Time  Number of cycles 
Initial denaturation 95 ̊C 2 min 1 
Denaturation 98 ̊C 30 sec 
×34 Primer annealing 60 ̊C 30 sec 
Extension 72 ̊C 30 sec – 2 min  
Final extension 72 ̊C 5 min – 10 min 1 
Cooling   4 ̊C ∞ 1 
 
Quantitative PCR was performed with FastStart Essential Green Master mix (Roche 
Holding AG, South Africa) according to manufacturer’s instructions. Each reaction was 
set up with 1× SYBR Green Master mix, 1 µM forward and reverse primer, 1 - 100 ng of 
template and nuclease free water up to a final volume of 20 µl. Primers used are shown on 
Table 2.1. PCR cycling conditions were set up as mentioned in Table 2.3. 
 
Table 2.3: qPCR cycling conditions 
Step Temperature Time Number of cycles 
Initial denaturation (hotstart) 95 ̊C 10 min 1 
Denaturation 95 ̊C 15 sec 
×40 Primer annealing 60 ̊C 15 sec 
Extension 72 ̊C 15 sec  
Melt curve 65 ̊C - 95 ̊C 5 sec - 50 sec 1 
Cooling   4 ̊C ∞ 1 
 
2.3.5 DNA ligation 
 
The ligation was performed with InsTAclone PCR Cloning Kit (Thermo Fisher Scientific, 
MA, USA), T4 DNA ligase kit (Thermo Scientific, MA, USA) or Fast-Linked DNA 
Ligation Kit (Epicentre Biotechnologies, WI, USA) according to manufacturer’s 
instructions. Each reaction contained 1× ligation buffer, 1µl T4 DNA ligase or 1 µl Fast-
Link DNA Ligase, 50 - 55 ng of plasmid and different ratios of insert to plasmid. The 
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reactions were made up to a final volume of 15 - 30 µl with nuclease free water. For Fast-
Linked DNA Ligations, ATP was included to a final concentration of 0.1 - 0.2 mM in the 
reactions. The ligation reactions were incubated overnight at 4 ̊C. Following the 
incubation, the ligation reactions were heat inactivated at 70 ̊C for 15 minutes. The entire 
mixtures were briefly spun down and transformed into suitable E. coli cells.  
 
2.3 Construction of HDAd plasmid backbones with the PEPCK promoter 
expression cassette 
 
The cloning was performed as illustrated in Figure 2.1 using standard procedures 
described above. To generate an intermediary plasmid expressing Firefly Luciferase from 
PEPCK promoter, a PCR based technique was used. The Firefly Luciferase sequence was 
PCR amplified from previously described plasmid pCI-neoCMVFluc [(Passman et al., 
2000), Table 2.4] using primer EcoRVF and EcoRVR (Table 2.1). The amplicon with the 
Eco RV engineered sites was then cloned into a PCR cloning vector, pTZ57R/T (Thermo 
Fisher Scientific, MA, USA) to generate pTZFluc. Sequencing of the positive clone to 
assess for PCR amplification errors was performed by Inqaba biotec- Africa's Genomics 
Company (Inqaba Biotec, Gauteng, South Africa). A plasmid bearing PEPCK promoter 
(pLPBL-pepck-wl-Swa-I-Spe I), was kindly donated by Phillip Ng, Houston Baylor 
College of Medicine. The Firefly Luciferase sequence was digested with Eco RV, purified 
and ligated downstream of PEPCK promoter into the Swa I site of the pLPBL-pepck-wl-
Swa-I-Spe I plasmid (pLPBL), to construct pLPBLFluc. The PEPCK promoter cassette 
was extracted by digestion with Asc I and sub-cloned into the HDAd genome bearing 
plasmid, pΔ24.7E4 (Table 2.4, kindly donated by Phillip Ng, Houston Baylor College of 
Medicine) to generate pPEPCKFlucHDAd. 
 
The anti-HBV sequences pri-miRNA 31/5 and pri-miRNA 31/589 sequences have 
previously been cloned into the Swa I site of pLPBL plasmid downstream of PEPCK 
promoter to construct pLPBL31/5 and pLPBL31/589 respectively (unpublished). The 
PEPCK promoter cassettes were isolated from pLPBL31/5 and pLPBL31/589 through 
restriction digests with Asc I. The fragments were excised and sub-cloned through ligation 
into the pΔ24.7E4 (kindly donated by Phillip Ng, Houston Baylor College of Medicine) 
Asc I site to generate pPEPCK31/5HDAd or pPEPCK31/589HDAd.   
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Table 2.4: Plasmids used and constructed during this study 
Plasmid Description  Reference/Source 
pCI-neoCMVFluc   Mammalian expression vector (pCI-neo) 
carrying the Firefly luciferase  gene 
(Passman et al., 
2000) 
pTZ57R/T TA cloning vector Thermo Fisher 
Scientific, MA, 
USA  
pTZFluc pTZ vector carrying the carrying the Firefly 
luciferase  gene 
This study 
pLPBL-pepck-wl-
Swa-I-Spe I (pLPBL) 
Plasmid carrying a PEPCK promoter  Kindly donated by 
Phillip Ng 
pLPBLFluc pLPBL-pepck-wl-Swa-I-Spe I plasmid 
expressing Firefly luciferase  gene from a 
PEPCK promoter 
This study 
pLPBL31/5 pLPBL plasmid expressing monocistronic 
anti-HBV pri-miR31/5 sequence from a 
PEPCK promoter 
This study 
pLPBL31/589 pLPBL plasmid expressing polycistronic 
anti-HBV pri-miR31/589 sequence from a 
PEPCK promoter 
This study 
pΔ24.7E4 A plasmid carrying the recombinant Helper 
Dependent Adenoviral vector (HDAd) 
genome  
Kindly donated by 
Phillip Ng 
pPEPCKFlucHDAd pΔ24.7E4 expressing Firefly luciferase 
gene from a PEPCK promoter 
This study 
pPEPCK31/5HDAd pΔ24.7E4 expressing monocistronic anti-
HBV pri-miR31/5 sequences from a 
PEPCK promoter 
This study 
pPEPCK31/589HDAd pΔ24.7E4 expressing polycistronic anti-
HBV pri-miR31/589 sequences from a 
PEPCK promoter 
This study 
pΔ28E4CMVlacZ Helper Dependent Adenoviral vector 
genome bearing plasmid expressing lacZ 
reporter gene from a CMV promoter 
(Palmer and Ng, 
2008a) 
pNG150D Plasmid containing segments of both 
Helper virus and Adenoviral genome 
sequences 
Kindly donated by 
Phillip Ng 
pCH-9/3091  HBV replication-competent plasmid that  
contains a greater than genome length HBV 
sequence 
(Nassal, 1992) 
psiCHECK-HBx Reporter plasmid with HBx sequence 
downstream of the Renilla luciferase ORF 
(Weinberg et al., 
2007) 
pCI-neo eGFP pCI-neo plasmids expressing enhanced 
green fluorescence protein (eGFP)  
(Passman et al., 
2000) 
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Figure 2.1: Construction of the anti-HBV and control HDAd genome bearing 
plasmids. 
To construct Fluc PEPCK promoter cassette and clone into p∆24.7E4, the Firefly 
luciferase (Fluc) orf was first amplified from the pCI-neoCMVFluc and ligated into 
pTZ57R/T major cloning site (indicated by blue block) to generate pTZ-Fluc. The Fluc 
was excised and subcloned downstream of PEPCK promoter in to pLPBL plasmids Swa I 
site to generate pLPBLFluc. The Fluc cassette and the previously constructed PEPCK 
cassettes with pri-miR 31/5 or pri-miR 31/589 sequence were excised with Asc I from 
pLPBL-pepck-wl-Swa-I-Spe I (pLPBL) and subcloned in to the Asc I site of Helper 
Dependent Adenoviral vector genome bearing plasmid (p∆24.7E4) to generate 
pPEPCKFlucHDAd or pPEPCK31/5HDAd or pPEPCK31/589HDAd. 
 
2.4 Tissue culture methods 
 
2.4.1 Cell-line culturing and maintenance  
 
HEK293T (kidney derived), 116 (HEK293 derived) and Huh 7 (human liver derived) cells 
were grown at optimum conditions in a humidified incubator at 37 ̊C and 5 % CO2. 
HEK293T and Huh 7 cells were grown in Dulbecco’s modified Eagles medium [DMEM, 
(Appendix 6.3)]. Eagle’s Minimum Essential Medium [EMEM, (Appendix 6.3)] was used 
for the growth of 116 cells. The medium was supplemented with 5 % or 10 % Fetal 
Bovine serum (FBS) (Life Technologies, CA, USA) and the antibiotic combination of 
Penicillin (100 000 U/ml) and Streptomycin (100 µg/ml) (Sigma-Aldrich, MO, USA). 
Suspension 116 cells were grown in Joklik Eagle’s Minimum Essential Medium [JEMEM, 
(Appendix 6.3)] supplemented with 5 % FBS, and the antibiotic combination of Penicillin 
(100 000 U/ml) and Streptomycin (100 µg/ml) and Hygromycin (0.1 mg/ml). 
 
To grow cells from a liquid nitrogen freezer stock, cells were first thawed by placing the 
cryovial containing the cells at 37 ̊C. The cells were added to 10 ml of 10 % FBS 
containing medium in a 15 ml flacon tube and spun at 800 rpm for 3 minutes. The pellet 
was resuspended in 2 ml of 10 % FBS containing medium and added to a 25 cm2 culture 
flask containing 3 ml of 10 % FBS containing medium. The cultures were incubated until 
the cells were 90-100 % confluent. HEK293T and 116 cells were detached by incubation 
with 3 ml of Saline-EDTA solution. However, Huh 7 requires trypsinisation, therefore the 
Saline-EDTA was substituted with 500 µl of 0.5× Triple express (Life Technologies, CA, 
USA). The cells were incubated at 37 ̊C and 5 % CO2 for 3 minutes. The flask was tapped 
lightly to ensure all cells were detached. To inactivate the 0.5× Triple express solution 
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(Appendix 6.3), 3 ml of 10 % FBS containing medium was added to the flask. The clumps 
in the suspended detached cells were broken by gently pipetting up and down. The 
suspended cells were transferred to a 75 cm2 culture flask and made up to a total of 10 ml 
with 10 % FBS containing medium.  The cultures were incubated until the cells were 90-
100 % confluent. The similar procedure was used for the passaging into 175 cm2 culture 
flask, whereby 5 ml Saline-EDTA solution or 1 ml of 0.5× Triple express solution was 
used. The suspended cells were transferred to a 175 cm2 culture flask and made up to a 
final volume of 20 ml with 10 % FBS containing medium. Splitting of cells followed the 
similar procedure, but the final detached suspension cells were divided either between two 
or three flasks, by transferring either half or a third of the volume to each of the flasks. 
The volume was adjusted to 10 ml for 75 cm2 flask or 20 ml for 175 cm2 flask with 10 % 
FBS containing medium. Passaging was continued until required number of flasks/cells 
have been obtained. The medium was replaced after every 48 hours. 
 
2.4.2 Transfection of eukaryotic cell lines 
 
Transfection of Huh 7 cells was carried out with LipofectamineTM 3000 reagent 
(Invitrogen, Thermo Fisher Scientific, MA, USA) according to manufacturer’s 
instructions.  Huh 7 cells were grown to 100 % confluency in a 75 cm2 flask and seeded in 
10 % DMEM into a 24 well plate at a density of 2.9 × 105 cells per well. Cells were 
incubated at 37 ̊C, 5 % CO2 overnight. One hour prior to transfection the media was 
replaced with 10 % FCS antibiotic-free DMEM. Each well was co-transfected with the 
DNA transfection mixture containing 100 ng of pCH-9/3091 (Nassal, 1992) or 
psiCHECK-HBx plasmid (Table 2.4), 100 ng of pCI-neo eGFP plasmid (Table 2.4), 0.2 µl 
P3000 Reagent (1 µl/µg DNA) and 50 µl of Opti-MEM medium. pCI-neo eGFP was 
added to the DNA transfection mixture to enable the determination of the transfection 
efficiency using fluorescence microscopy. Firstly, DNA mix was prepared by mixing 200 
ng DNA with 50 µl of Opti-MEM and a lipofectamine mix by mixing 0.2 µl of 
LipofectamineTM 3000 reagent with 50 µl of Opti-MEM (Lipofectamine mixture). The two 
solutions were incubated at room temperature for 5 minutes followed by combining and 
further incubation for 15 minutes. A 100 µl of the transfection mixture was added to each 
well, and incubated for 5 hours at 37 ̊C.  
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Transfection with Polyethylenimine “Max’ (PEI max) entailed adding 30 µg of PEI max 
(Fluke®, Sigma-Aldrich, MO, USA) to 500 µl of Opti-MEM and 10 µg of linearized 
plasmid DNA to 500 µl of Opti-MEM (Life Technologies, CA, USA) separately. The 
solutions were incubated at room temperature for 10 minutes. The solutions were then 
mixed together, incubated at room temperature for 20 minutes and added dropwise to the 
116 cells in a 60 mm plate. 
 
2.4.3 AdNG163 and Ad163Cys Helper virus amplification 
 
HEK293T cells were grown to 100 % confluency in a 175 cm2 flask. The HEK293T cells 
were counted and plated to 1.5 × 105 cells/ml in a total volume of 15 ml in a 143 cm2 
plate. The cells were immediately infected with a previously produced helper virus at a 
MOI (multiplicity of infection) of 0.1. Medium change was performed every 48 hours for 
10 days, whereby the medium was removed and centrifuged at 1000 rpm for 3 minutes. 
The supernatant was discarded, the pellet was then resuspended in 15 ml of 5 % FBS 
DMEM and added back to the plate. On the 10th day the cells were harvested into the 
supernatant and 1.5 ml of 40 % sucrose was added. The helper virus stocks were subjected 
to 3× freeze thaw cycles and stored at -80 ̊C. 
 
2.4.4 Immunostaining for Ad helper virus infectious units determination 
 
HEK293T cells were grown to 90-100 % confluency with 10 % FBS DMEM in a 75 cm2 
culture flask. The HEK293T cells were seeded into a 24 well plate at ~ 50 % confluency 
with 500 µl of 10 % FBS DMEM per well. Cultures were incubated overnight (to reach 
confluency ~ 90 %) and the medium was removed the following day. Cells were infected 
with serial dilutions of the AdNG163 or AdNG163Cys helper virus (10-1 to 10-5) by 
adding 100 µl per well of each dilution in duplicate. The infected cells were incubated at 
37 C̊ and 5 % CO2 for 1 hour rocking the plate every 10 minutes. The remainder of 400 µl 
of 5 % FBS DMEM was added to the wells. The cells were then incubated for 48 hours at 
37 C̊ and 5 % CO2.  
 
Immunostaining was performed using the Ultra-Sensitive ABC Peroxidase Mouse IgG 
staining kit (Thermo Fisher Scientific, MA, USA) according to the manufacturer’s 
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instructions with minor adjustments. Medium was removed and cells were left to air dry 
for 5 minutes. Cells were fixed with 300 µl methanol for 20 minutes at -20 ̊C. Cells were 
washed 3× with phosphate-buffered saline [PBS, (Sigma-Aldrich, MO, USA)] + 0.5 % 
bovine serum albumin [BSA, (Roche Holding AG, South Africa)]. Five drops of blocking 
buffer (3 drops blocking serum + PBS) was added to each well and incubated at room 
temperature for 5 minutes. Blocking solution was removed and cells were washed once 
with PBS + 0.5 % BSA. Permeabilization of cells was performed by adding 300 µl of 
permeabilization buffer (PBS + 0.5 % BSA + 0.25 % Triton-X) and incubating cells at 
room temperature for 5-10 minutes. Permeabilization solution was removed and cells were 
washed once with PBS + 0.5 % BSA. Cells were then incubated with 300 µl of mouse 
anti-Ad fiber Primary antibody (Biocom Biotech, Gauteng, South Africa, 1000× dilution 
in blocking serum) for 1 hour at room temperature. The mouse anti-Ad fiber Antibody 
(Ab) was removed and cells were washed 3× with PBS + 0.5 % BSA. Five drops of 
Biotinylated secondary Ab was added to the cells and incubated for 30 minutes at room 
temperature. Cells were then washed 1× with PBS + 0.5 % BSA. Five drops of Detector 
ABC reagent [horseradish peroxidise (HRP) complexed with avidin] was added to the 
cells and incubated at room temperature for 30 minutes. ABC reagent was removed and 
cells were washed 1×  with PBS + 0.5 % BSA. The metal enhanced substrate, 3,3'-
Diaminobenzidine (DAB) chromagen diluted solution [1 ×  DAB+ hydrogen peroxide 
(H2O2,) Roche Holding AG, South Africa] was added to the cells and incubated for 10 
minutes at room temperature in a dark area. The Ad infected cells produced a dark brown 
colour. The positively stained cells were viewed and counted under a light microscope. 
The infectious units (ifu)/ml of the Ad helper virus was determined with the following 
formula and fields per well as indicated on Table 2.5:  
 
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑖𝑓𝑢/𝑚𝑙:
(𝑖𝑛𝑓𝑒𝑐𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 𝑓𝑖𝑒𝑙𝑑) × (𝑓𝑖𝑒𝑙𝑑𝑠 𝑝𝑒𝑟 𝑤𝑒𝑙𝑙)
𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑣𝑖𝑟𝑢𝑠 (𝑚𝑙) × 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟
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Table 2.5: Derivation of Area counted in fields/wells 
Objective 
Lenses 
Fields/wells 
12 well plate 
area = 3.8 cm2 
24 well plate 
area = 2.0 cm2 
96 well plate 
area = 0.32 cm2 
4× 19 10 1.6 
5× 30 16 2.6 
10× 150 79 12.6 
20× 594 313 50 
 
2.4.5 Transmission Electron Microscopy (TEM) 
 
TEM of HV was performed at The National Institute for Communicable Diseases at the 
NHLS according to a published protocol (Goldsmith and Miller, 2009) with adaptions. 
Briefly, the HV containing samples were placed onto 0.25 % formvar-coated 300 mesh 
copper grids and incubated for 5 minutes. The grids coated with the samples were then 
stained with 4 % aqueous uranyl acetate for 5 minutes and dried overnight at room 
temperature.  The samples were viewed at 80kV on a FEI BioTwin Spirit TEM. Imaging 
was performed with Olympus Quemesa CCD camera.  
 
2.4.6 HDAd production and purification 
 
HDAd production and amplification 
 
The HDAd production was performed according to a published protocol with slight 
adjustments (Palmer and Ng, 2008b). Briefly, HDAd genome bearing plasmid was 
digested with Pme I (New England Biolabs, MA, USA), thereby liberating the HDAd 
genome from the bacterial sequence. The 116 cells were seeded into a 60 mm dish and 
grown to 70 % confluency. The cells were then transfected overnight with the linearized 
HDAd plasmid using a 3:1 ratio of PEI max:DNA (section 2.4.2, Fluke®, Sigma-Aldrich, 
MO, USA) to plasmid. After overnight incubation, media was removed from transfected 
cells and cells were washed once with media supplemented with 5 % FCS. Helper virus at 
a MOI of 5 in 500 µl of 5 % FCS containing media was added to the cells  and incubated 
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at 37 0C and 5 % CO2 for 1 hour rocking the plate every 10 minutes, The media was then 
topped up to 2.5 ml and incubated for 48 hours to allow selective HDAd production. Cells 
were harvested, supplemented with sucrose to 4 % and lysed by 3 cycles of freeze 
thawing.  
 
HDAd amplification was performed by sequential co-infections of 116 cells in a 60 mm 
dish with HV at MOI of 2 and 400 µl of HDAd containing lysate from the previous 
passage until optimum HDAd titers were reached in a 60 mm plate. About 70 % confluent 
116 cells in a 150 mm dish were co-infected with 500 µl HDAd containing lysate from the 
lowest  passage with the highest titers and helper virus at a MOI of 2 as described above 
using 2 ml infection volume, which was topped up to 15 ml with 5 % FCS containing 
media. The co-infected cells were harvested after 48-72 hours [100 % Cytopathic effect 
(CPE)]. The harvested cells were centrifuged at 7500 rpm for 5 minutes, supernatant was 
discarded and the pellet was resuspended in 1 ml of 100 mM Tris-HCl (pH 8) and 
continued with large scale production. Due to the HDAd vectors being lac Z deficient, a 
HDAd vector expressing lac Z (HDAdLacZ) was amplified in parallel to aid as a 
amplification control, as well as to provide a mean of quantifying the number of infectious 
units after each amplification step of the HDAd vectors.  
 
2.4.7 X-gal staining for HDAd infectious particles determination  
 
The 116 or HEK293 cells were grown to 90-100 % confluency with 10 % FBS EMEM in 
a 75 cm2 culture flask. The 116 cells were seeded into a 24 well plate at 50 % confluency 
with 500 µl of 10 % FBS EMEM per well. Plates were incubated overnight (to reach 
confluency ~ 90 %) and the medium was removed the following day. The cells were then 
infected with undiluted or serial dilutions (100-10-6) of HDAdLacZ as described in section 
2.4.4. The plate was incubated for 48 hours at 37 ̊C and 5 % CO2. 
 
After 48 hours the medium was removed, cells were left to air dry for 5 minutes at room 
temperature. A fixative solution (1 % formaldehyde; 0.5 % glutaraldehyde in PBS) was 
then added (300 µl) gently and incubated at room temperature for 10 minutes to fix the 
cells to the plate. The fixative was removed and cells were washed twice with 300 µl of 
1× PBS. The X-gal staining solution [(300 µl), 4 mM potassium ferricyanide; 4 mM 
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potassium ferrocyanide; 2 mM MgCl2; 0.4 mg/ml X-gal, Appendix 6.3] was added to the 
cells and incubated at 37 ̊C and 5 % CO2 for 3-16 hours. The X-gal positive cells produced 
a blue colour and was counted to determine the infectious units. The number of ifu/ml was 
determined using the formula and Table 2.5 as indicated in section 2.4.4. 
 
Large scale HDAd production, purification and quantification 
 
Large scale production was performed with 116 cells in suspension. Suspension cells were 
prepared by growing 8 large flask of 116 cells to 100 % confluency. The cells were 
detached with 5 ml of Saline-EDTA and incubation for 3 minutes at 37 ̊C. The cells were 
transferred into 50 ml falcon (2 flasks/falcon) and centrifuged for 3 minutes at 1000 rpm. 
The pellets were resuspended in 5 ml of 5 % JEMEM (Appendix 6.3) and transferred to 
two 1.5 L spinner flasks (4 flasks per spinner flask). Fresh 5 % JEMEM was added to each 
spinner flask to a final volume of 500 ml. The spinner flasks were incubated overnight at 
37 C̊ spinning at 60 rpm. The following day the cells were counted and 250 ml of 5 % 
JEMEM was added to each spinner flask and incubated overnight at 37 ̊C spinning at 60 
rpm. This was repeated after 48 hours. On the 3rd day the medium was made up to a final 
volume of 1.5 L. In between each feeding the cells were counted, when cells were at a 
density of 2 × 105 to 4 × 105 cells/ml in 1.5 L, coinfection was performed. Cell count was 
performed by transferring 2 ml of the cells into a 15 ml falcon tube. Two milliliters of 2× 
citric saline pre-heated at 37 ̊C was added and cells were votexed for 10 seconds. The cell 
mixture was incubated at 37 ̊C for 10 minutes, followed by votexing for 10 seconds. Fifty 
microliters of cells were added to 50 µl of Trypan blue. Cells were counted and multiplied 
by the dilution factor of 4 to obtain the total number of cells/ml. To monitor cell health 
and growth, after each cell count and addition of media, 100 µl of cells were added to 500 
µl of 5 % JEMEM in a 24 well plate.  
 
Co-infection was performed by harvesting the suspension cells by centrifugation at 7500 
rpm for 5 minutes at room temperature. The pellet was resuspended in 100 ml of spent 
media and transferred to a 250 or 500 ml spinner flask. The resuspended cells were then 
co-infected with helper virus at a MOI of 2 and the 1 ml of HDAd obtained from the 150 
mm plate. The cells were incubated for 2 hours at 37 ̊C spinning at 60 rpm. After 2 hours, 
50 ml of co-infected cells were transferred to each of the 1.5 L spinner flasks containing 
250 ml spent media and made up to a final volume of 1 L with 5 % JEMEM. A 100 µl of 
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the co-infected cells were added to a well containing 500 µl of 5 % JEMEM. This was to 
monitor the health of the cells, whereby 100 % rounding up of cells should be seen after 
48 hours. The co-infected cells were incubated for 48 hours at 37 ̊C spinning at 60 rpm. 
After 48 hours, co-infected cells were harvested by centrifugation at 7500 rpm for 5 
minutes at room temperature. The supernatant was discarded and the pellet was 
resuspended in 15 ml 100 mM Tris-HCl (pH 8) and transferred into a 15 ml falcon tube.  
 
Two milliliters of 5 % sodium deoxycholate was added to the cells and incubated for 30 
minutes at room temperature mixing every 5 minutes. A volume of 170 µl of 2 M MgCl2, 
150 µl RNAse (10 mg/ml) and 150 µl DNAse (10 mg/ml) was added to the mixture and 
incubated for 1 hour at 37 ̊C, mixing every 10 minutes.  The mixture was then centrifuged 
at maximum speed for 10 minute at room temperature using a tabletop centrifuge. The 
CsCl step gradient was then prepared as follows (2 per virus): 2 ml of 1.35 g/ml CsCl was 
added slowly to the ultraclear ultracentifuge tube, 3 ml of 1.25 g/ml CsCl was then added 
drop wise to the side of the tube to ensure that the gradient is not disturbed. The virus 
containing supernatant was then overlaid carefully by adding dropwise to the side of the 
tube. The tubes were then centrifuged at 35000 rpm for 1 hour at 4 ̊C. Using a 22 gauge 
needle, the HDAd virus (lowest band) was extracted and transferred to a new tube. The 
tube was filled up with 1.35 g/ml CsCl and centrifuged at 35000 rpm overnight at 4 ̊C. 
Using a 22 gauge needle the HDAd virus band was extracted and transferred to a Slide-A-
Lyzer cassette presoaked in 10 mM Tris-HCl (pH 8) dialysis buffer. The virus was 
dialyzed at 4̊C, with dialysis buffer changed twice every 3 hours and then left to dialyze 
overnight at 4 ̊C. Following dialysis, the virus was extracted from the dialysis cassette 
using a 22 gauge needle and glycerol was added to a final concentration of 10 % and 
mixed well. The purified virus was then aliquoted into 50 µl stock and stored at -80 0C.  
 
To determine the absolute quantities of HDAd and HV in the CsCl purified viral 
preparations, viral DNA was isolated (section 2.2.3) from 50 µl of purified virus and used 
for qPCR. Standards were set up with dilutions prepared from a designed pNG150D Ad 
plasmid containing both HV and HDAd sequences (Donated by Phillip Ng, Houston 
Baylor College of Medicine). Q-PCR was performed with primer sets HVF and HVR or 
HDAdF and HDAdR (Table 2.1) under the qPCR cycling conditions as indicated in Table 
2.3.  
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2.4.8 Assessment of in vitro Firefly luciferase expression 
 
Firefly luciferase expression in Huh 7 cells were determined using the Dual-Luciferase® 
Reporter Assay System (Promega, WI, USA) with slight adjustment. Briefly, Huh 7 cells 
were infected with PEPCKFlucHDAd at a MOI of 2000 and incubated at 37 ̊C for 72 
hours. The media was removed and cells were harvested with 1× Lysis buffer (100 µl per 
well). Ten microliters of lysate was transferred into a well of a luminometer plate. Fifty 
microliters of LAR II (Luciferase assay substrate, 50 µl per sample) substrate was added 
to the well containing the sample, followed by luminescence measuring using the Veritas 
Microplate Luminometer (Turner BioSystems, CA, USA). 
 
2.4.9 Determination of pri-miR in vitro expression 
 
2.4.9.1 Northern blot analysis 
 
Northern blotting was performed according to previously described protocol (Crowther et 
al., 2016). For in vitro expression analysis, Huh 7 cells were seeded into a 10 cm dish at a 
density of 1.05 ×  107 cells per dish and infected with empty HDAd24.7E4 or 
PEPCK31/5HDAd or PEPCK31/589HDAd at a MOI of 0 or 1000. Cells were incubated at 
37 ̊C for 48 hours. The cells were harvested by centrifugation at 800 rpm for 5 minutes 
and resuspended in 1ml TRIzol reagent and total RNA was extracted.      
  
RNA extraction with Trizol reagent 
 
Lysates were incubated at room temperature for 5 minutes. Chloroform (200 µl per 1 ml of 
TRIzol reagent, Ambion, Thermo Fisher Scientific, MA, USA) was added to the lysates, 
shaken vigorously for 15 seconds and incubated at room temperature for 2-3 minutes. The 
lysates were centrifuged at maximum speed for 15 minutes at 4 ̊C. The top aqueous layer 
was transferred to a fresh tube and 500 µl of isopropanol was added per 1 ml of TRIzol 
reagent. Mixture was incubated at room temperature for 10 minutes and centrifuged at 
maximum speed for 10 minutes at 4 ̊C. Supernatant was removed and pellet was washed 
with 1 ml of 75 % ethanol (in Sabex or DEPC water). The sample was centrifuged at 
maximum speed for 5 minutes at 4 ̊C, supernatant was removed and RNA was air-dried 
for 5-10 minutes. RNA pellets were dissolved in 50-700 µl of Sabex water (RNAse free 
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water) depending on the RNA pellet size. The RNA concentration was determined using 
Nanodrop® Spectrophotometer (Thermo Fisher Scientific, MA, USA), aliquoted into 30 
µg aliquots and stored at -80 ̊C. 
 
Radioactive labelling of probes 
 
Radioactive probes (Table 2.6) were labelled in a 20 µl reaction. This entailed the addition 
of 2 µl of 10 µM probe stock, 2 µl of PNK buffer A (Thermo Fisher Scientific, MA, 
USA), 1 µl of T4 Polynucleotide Kinase (PNK, Thermo Fisher Scientific, MA, USA), 1 µl 
of radioactive [γ-32P]-ATP (PerkinElmer, MA, USA) and Sabex water to a final volume of 
20 µl. Probe mixture was incubated at 37 ̊C for 45 minutes. Sephadex columns were 
prepared for the purification of the probe by inserting 1 cm of compact filter fiber into a 1 
ml syringe. The syringe was then filled with sephadex (Appendix 6.4) and placed into a 15 
ml falcon tube. The column was centrifuged at 2000 rpm for 2 minutes and topped up with 
sephadex, followed by centrifugation at 2000 rpm for 2 minutes. This was continued until 
the sephadex reached 0.9 ml. The probe was diluted to 50 µl by adding 30 µl of sabex 
water and transferred to the sephadex column. The columns were centrifuged at 2000 rpm 
for 2 minutes and the purified probes were stored at 4 ̊C.  
 
Radioactive labelling of RNA decade marker 
 
The decade marker was labelled by mixing 1 µl of Decade marker (100 ng) , 6 µl 
Nuclease free water, 1 µl 10 ×  Kinase reaction Buffer A (Ambion, Thermo Fisher 
Scientific, MA, USA), 1 µl of radioactive 32P [[γ-32P]-ATP, (PerkinElmer, MA, USA)] and 
1 µl PNK (Ambion, Thermo Fisher Scientific, MA, USA). The mixture was incubated at 
37 ̊C for 1 hour. After incubation, 8 µl of Nuclease free water and 2 µl of 10× Cleavage 
reagent (Ambion, Thermo Fisher Scientific, MA, USA) was added to the mixture and 
incubated at room temperature for 5 minutes. Twenty microliters of Gel loading buffer II 
(Ambion, Thermo Fisher Scientific, MA, USA) was then added to the ladder mixture and 
stored at -80 ̊C. 
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Polyacrylamide gel electrophoresis, blotting and exposure  
 
A 15 % polyacrylamide gel was set the day before by mixing 0.45 g bis-acrylamide 
(Merck Chemicals (Pty) Ltd, Darmstadt, Germany), 8.55 g acrylamide (Merck Chemicals 
(Pty) Ltd, Darmstadt, Germany), 28.8 g Urea (Merck Chemicals (Pty) Ltd, Darmstadt, 
Germany) and 6 ml of 10× TBE buffer. About 20 ml of sabex water was added and the gel 
mixture was dissolved in warm water stirring. Once dissolved, the final volume was made 
up to 60 ml with Sabex water and the gel was cooled to room temperature. After adding 
300 µl of 1 % APS and 30 µl of TEMED (Sigma, MO, USA), the gel was immediately 
poured and left overnight to set at room temperature.  
 
Before loading of samples and decade marker, the gel was pre-run with 1× TBE running 
buffer (Appendix 6.4) at 150 V for 30 minutes. Samples were prepared by adding equal 
amount of loading dye (Ambion, Thermo Fisher Scientific, MA, USA) to 30 µg of RNA 
and denatured at 80 ̊C for 5 minutes. The ladder was prepared by mixing 5 µl of Decade 
marker, Sabex water to the highest volume of RNA sample and equal amount of loading 
dye. The ladder was denatured at 95 ̊C for 5 minutes. Samples and ladder were placed on 
ice to prevent renaturing.  The ladder and samples were loaded and ran at 150 V for 1 hour 
followed by increasing the voltage to 200 V until front dye has reached the bottom. The 
gel was stained with Ethidium bromide (10 µl per 100 ml of 1× TBE running buffer) for 5 
minutes and viewed using the Syngene G:BOX Gel Documentation and Analysis system 
(Syngene, England, UK) to verify equal loading. The RNA was blotted onto a Hybond-N+ 
positively charged nylon membrane (Amersham, NJ, USA) at 4 ̊C using the Semi-Dry 
Electroblotting Unit Z34,050-2 (Sigma-Aldrich, MO, USA) at 3.3 mA/cm2 (0.77A) for 45 
minutes. The membrane was then UV Crosslinked for ~2 minute (20 000 µJ/cm2) using a 
Ultra-Violet Products (UVP) UV cross linker (UVP Inc., CA, USA). After UV cross-
linking the membranes were pre-hybridized for 20 minutes with 10 ml of pre-heated 
hybridization buffer at 42 ̊C. The [γ-32P]-ATP labelled probes (Table 2.6) were denatured 
at 95 ̊C for 5 minutes and added to the buffer. The membranes were then hybridized 
overnight at 42 ̊C. Following overnight hybridisation, membranes were washed once with 
50 ml of 0.1 % SDS (sodium dodecylsulphate) and 5× SSC (NaCl, Nacitrate, Sigma, MO, 
USA) at room temperature for 20 min. Subsequently the membranes were then washed 
twice with 50 ml of 0.1 % SDS and 1× SSC at 42 ̊C for 15 minutes. The membranes were 
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exposed to a phosphoimager plate for 7 days and decade marker was exposed overnight at 
room temperature in the dark. The phosphoimaging was performed using the FUJIFILM 
FLA-7000 instrument with the FLA-7000IR software (Vacutec, Gauteng, SA). 
 
Table 2.6: Sequences of probes used for detection of 5, 8 and 9 pri-miR guide 
sequences 
 
 
2.4.10 Assessment of HBV surface antigen knockdown in Huh 7 cells  
 
2.4.10.1 Assessment of HBV gene silencing using ELISA  
 
After 5 hours of transfection with pCH-9/3091, the medium was removed and cells were 
infected in quadruplicate with HDAd24.7E4 or PEPCK31/5HDAd or 
PEPCK31/589HDAd at a MOI of 0, 1000, 2000, 10000 and 20000. The 100 µl infection 
solution was added dropwise to the allocated wells and incubated at 37 ̊C, rocking every 
10 minutes. Each well was then topped up to a final volume of 500 µl with 5 % DMEM 
and incubated at 37 ̊C. After 48 hours, supernatant was collected from the infected cells. 
The HBV replication knockdown was assessed by measuring the secreted HBV surface 
antigen (HBsAg) in the supernatant by performing ELISA using the Monolisa™ HBsAg 
Ultra Kit (Bio-Rad Laboratories, CA, USA) according to the manufacturer’s instructions. All 
solutions were prepared as indicated before use. Briefly, 100 µl of sample supernatant was 
added to a 96 well plate and 50 µl of conjugate was then added to each well and incubated at 
37 ̊C for 1 hour 30 minutes. The wells were aspirated and washed 4 times with washing 
solution. The plate was blotted to ensure all liquid was removed and 100 µl of developing 
solution was added to the well, followed by incubation at room temperature for 30 minutes in 
a dark area. Stopping solution of 100 µl was then added to each well and incubated for 4 
minutes at room temperature. Optical density (OD) was measured at 490/655 nm using the 
iMARK, Microplate Reader (Bio-Rad Laboratories, CA, USA). 
 
Probe type Sequence- 5’- 3’ Reference 
Probe 5 5’ CCGTGTGCACTTCGCTTC ‘3 
(Crowther et al., 2016) Probe 8 5’ CAATGTCAACGACCGACC ‘3 
Probe 9 5’ TAGGAGGCTGTAGGCATA ‘3 
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2.4.10.2 Assessment of HBV gene silencing using Dual Luciferase assay  
 
The efficiency of pri-miR in HBV knockdown was further determined using the Dual-
Luciferase® Reporter Assay System (Promega, WI, USA) according to manufacturer’s 
instructions. After 5 hours of transfection with psiCHECK-HBx, medium was removed 
and cells were infected with empty HDAd24.7E4 or PEPCK31/5HDAd or 
PEPCK31/589HDAd at a MOI of 0 or 2000 or 10000 or 20000 in quadruplicate. Infected 
cells were incubated at 37 ̊C for 48 hours. The medium was removed and cells were lysed 
with 100 µl of 1× Lysis buffer per well. Ten microliters of lysate was dispensed into a 
well of a luminometer plate. Both the sample plate, 50 µl/well of LARII and 50 µl/well of 
1× Stop and Glo substrate were put in the luminometer and luminescence was measured 
with the Veritas Microplate Luminometer (Turner BioSystems, USA). The HBV 
knockdown was measure as a ratio of Renilla luciferase: Firefly luciferase expression.  
 
2.5 In vivo methods 
 
HBV transgenic mice used in this study have a greater than genome length HBV 
sequences integrated into their genome (Nassal, 1992). All experiments were carried out in 
accordance with the protocol accepted by the University of the Witwatersrand Animal 
Ethics Screening Committee. Mice were grouped in either 4, 5 or 6 mice. All sampling, 
handling, injections and general care of animals was done under the supervision of the 
WITS Central animal services (CAS) and senior investigators.  
 
Single dose of 1 × 1010 viral particles (vps) for HDAd24.7E4 or PEPCK31/589HDAd or 
PEPCKFlucHDAd was injected through tail vein injection. Poly (I:C) required during 
cytokine levels analysis was injected through hydrodynamic injection (10 % of the body 
weight). Blood sampling was performed with mice subjected to 30 seconds of isofluorane 
anesthetics prior to retro-orbital puncture. For serum harvesting, blood was incubated at 4 C̊ 
for 2 hours and centrifuged at 8000 rpm for 10 minutes at 4 ̊C. The top serum layer was 
transferred to fresh tubes and stored at -80 ̊C. Mice sacrificed for liver harvesting were 
euthanized by CO2 exposure and livers reserved for DNA (in saline) and RNA isolation 
(in Trizol). For Bioluminescence imaging, mice were anesthetized with isofluoran before 
imaging.  
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2.5.1 Assessment of in vivo expression of Firefly luciferase 
 
To assess the in vivo expression of Firefly luciferase, mice infected with 
PEPCKFlucHDAd were injected intraperitoneally with luciferase substrate D-luciferin 
[0.1 % of the body weight, (PerkinElmer, MA, USA)] after 3 days, 14 days and 28 days. 
The mice were immediately subjected to anesthesia with isofluorane and imaged using 
Xenogen IVIS® imaging system (PerkinElmer, MA, USA). Bioluminescence was quantified 
using the Living Image® software (PerkinElmer, MA, USA). 
 
2.5.2 Assessment of in vivo HBV replication inhibition and pri-miR expression  
 
The HBV surface antigen knockdown in mice was measured using 100 µl of 50× diluted 
serum from mice injected with saline or HDAd24.7E4 or PEPCK31/589HDAd at 1 and 2 
weeks post injection. This was performed by ELISA using the Monolisa™ HBsAg Ultra 
Kit (Bio-Rad Laboratories, CA, USA) as instructed by the manufacturer and summerised in 
section 2.4.10.1. Plate readings were performed with the iMARK, Microplate Reader (Bio-
Rad Laboratories, CA, USA).  
 
To determine pri-miR expression and processing, RNA was isolated from livers collected 
from mice after 1 week injection with saline or HDAd24.7E4 or PEPCK31/589HDAd. 
Livers were harvested and homogenized in TRIzol reagent. RNA was the isolated and 
used for Northern blotting as described in section 2.4.9. 
 
2.5.3 Evaluation of liver transduction 
 
Liver tissue obtained from HDAd infected mice was used for the preparation of viral DNA   
using QIAamp DNA Mini Kit (Qiagen, MD, USA) as per manufacturer’s instructions and 
summarised in section 2.2.3. Q-PCR was performed as indicated in section 2.3.3 under the 
cycling conditions in Table 2.3 with 100 ng of the prepared DNA and primers specific for 
the HDAd vector (Table 2.1). 
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2.5.4 Quantification of inflammatory cytokines using CBA assay 
 
To determine if an inflammatory response is activated by the administration of HDAds, 
inflammatory protein markers IL6, IL10, IL-12p70, IFN-γ, MCP-1 and TNF were 
measured at 0 days, 6 hours and 24 hours post infection in mice serum samples using a BD 
Cytometric Bead-Based array mouse inflammation kit (BD Biosciences, CA, USA), as 
instructed by the manufacturer. Briefly, the lyophilized Mouse inflammation standards 
were resuspended in 2 ml assay diluent, allowed to equilibrate for 15 minutes at room 
temperature and serial dilutions performed. Capture beads for each cytokine were vortexed 
and 10 µl/sample of each was mixed into a single tube. The mixed capture beads were 
vortexed and 50 µl was added to each assay tube. Fifty microliters of the prepared 
standards and undiluted mice serum samples were added to the appropriately labelled 
assay tubes containing the beads. Mouse Inflammatory PE Detection Reagent (50 µl) was 
added to assay tube and incubated for 2 hours at room temperature, protected from light. 
After incubation, 1 ml of wash buffer was added to each assay tube and centrifuged at 
2000 rpm for 5 minutes. The supernatant was carefully removed ensuring not to disrupt or 
remove the beads (pellet). Wash buffer (300 µl) was then added to the assay tube and 
vortexed. Cytometric bead array was conducted on the samples with the BD, 
LSRFortessaTM flow cytometry instrument and the BD CBA Software (BD Biosciences, 
CA, USA) was used to quantify the levels of inflammatory cytokines.  
 
2.5.5 Serum transaminase assay 
 
The safety of anti-HBV adenoviral vectors in vivo was assessed, by obtaining blood from 
the mice at 0 days (before infection), as well as 72 hours, 1 week and 2 weeks post 
infection. Alanine transferase (ALT) was assessed as a marker of liver toxicity. The ALT 
activity assay was carried out with the use of a kinetic assay on an automated photomeric 
analyser (Roche Diagnostics, Rotkreuz, Switzerland) by the National Health Laboratory 
Service chemistry Laboratory (NHLS). 
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2.5.6 Statistical analysis 
 
Data was expressed as the mean ± standard error of the mean (SEM). Statistical difference 
was calculated and performed using GraphPad Prism software package (GraphPad 
Software Inc., CA, USA) and Microsoft Excel. Statistical differences was considered to be 
significant when Student’s paired or unpaired Two-tailed T test indicated P<0.05. 
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CHAPTER 3 
 
3 RESULTS 
 
3.1 Construction of Helper Dependent Adenoviral vector plasmids bearing 
PEPCK promoter expression cassettes 
 
Non-specific tissue expression and immune stimulation by β-galactosidase encoded by a 
lac Z selection marker has been suggested to result in short-term HBV inhibition by RNAi 
activators expressed from adenoviral vectors (Crowther et al., 2014, Mowa et al., 2014). 
To overcome these obstacles and improve HBV silencing, HDAd vector genomes 
deficient of lac Z and expressing previously described anti-HBV pri-miR mimics 
(targeting specific sites within the HBx ORF of HBV) from a liver specific PEPCK 
promoter were constructed. Lac Z deficient HDAd genome plasmid was donated by 
Phillip Ng (p∆24.7E4, Baylor college of Education, USA).  
 
Construction of Firefly luciferase expressing HDAd plasmid 
 
To use as a convenient confirmation of PEPCK promoter activity, HDAd plasmid carrying 
the Firefly luciferase (Fluc) gene downstream of the PEPCK promoter was constructed. 
Fluc ORF was amplified from previously constructed pCI-neoCMVFluc (Passman et al., 
2000) by PCR and cloned into plasmid pTZ57R/T (Appendix 6.6) to generate pTZ-Fluc. 
The clones that were positive for the Fluc insert (1811 bp) were identified with Eco RV 
restriction digest (not shown). One positive clone was selected, plasmid DNA was 
prepared in large scale and digested with multiple restriction enzymes. The pTZ-Fluc 
plasmid was digested with Dra I and Sca I and compared to an empty pTZ57R/T plasmid 
digested with Dra I and Sca I (Table 3.1). The larger expected bands were present after 
digestion, however the 19 base pairs (bp) band was not visible due to its small size (Figure 
3.1). This confirmed successful cloning of the Fluc gene into the pTZ57R/T plasmid. The 
positive pTZ-Fluc construct was then sent for sequencing. The sequence was aligned with 
the parental sequence and 100 % alignment was observed (Appendix 6.5), validating that 
the complete Fluc insert was present and that the Fluc gene sequence was correct. 
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Table 3.1: Expected bands sizes for pTZFluc validation after restriction digest 
Plasmid type Enzyme Type Expected base pair sizes 
pTZ57R/T 
Dra I 2175 bp, 692 bp and 19 bp 
Sca I 2886 bp 
pTZFluc 
Dra I 3986 bp, 692 bp and 19 bp 
Sca I 2623 bp, 1853 bp and 221 bp 
Fragments in red are too small to visualize  
 
Figure 3.1: Validation of pTZ positive clone for Fluc gene insert.  
1 % Agarose gel of a positive pTZFluc clone and empty pTZ57R/T plasmid digested with 
Dra I and Sca I. Base pair sizes were determined with O’ GeneRuler DNA Ladder 
(Thermo Fisher Scientific, MA, USA). 
 
To clone Fluc downstream of the PEPCK promoter, the Eco RV excised Fluc sequence 
was ligated into the Swa I site of a pLPBL plasmid. Positive clones for pLPBLFluc were 
identified with Dra I restriction digest (not shown). Figure 3.2 represents a positive 
pLPBLFluc construct digested with Asc I, Bam HI, Dra I and Nhe I. The construct digests 
were compared to an empty pLPBL (Appendix 6.6) plasmid digested with the Asc I, Bam 
HI, Dra I and Nhe I to confirm the presence of the Fluc insert. The expected bands shown 
in Table 3.2 were present with the base pairs in blue migrating close together and could 
not be differentiated, indicating the presence of the Fluc insert. In order for the Fluc insert 
to be expressed from PEPCK promoter, it is required to be in a forward orientation, which 
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was determined with Nhe I digest. The pLPBLFluc construct shown on Figure 3.2 was 
found to be in a forward orientation (Appendix 6.6) with the banding pattern of 9790 bp 
and 393 bp, and was therefore used for further cloning. 
 
Table 3.2: Expected bands sizes for pLPBLFluc for validation and orientation 
confirmation 
Plasmid Enzyme Expected base pair sizes 
pLPBL 
Asc I 5465 bp and 2916 bp 
Dra I 
2887 bp, 1605 bp, 1506 bp, 1335 bp, 692 bp, 337 bp 
and 19 bp 
Nhe I 8381 bp 
Bam HI 4209 bp, 3229 bp, 661 bp and 282 bp 
pLPBLFluc 
Asc I 7266 bp and 2916 bp 
Dra I 
5026 bp, 1605 bp, 1506 bp, 1335 bp, 692 bp and 19 
bp 
Nhe I (forward) 9790 bp and 393 bp 
Nhe I (reverse) 8130 bp, 2053 bp 
Bam HI 5031 bp, 4209 bp, 661 bp and 282 bp 
Fragments in blue migrate close together and red are too small to visualize  
 
Figure 3.2: Validation of a positive clone containing Fluc gene into the pLPBL 
plasmid.   
Agarose gel of the empty pLPBL plasmid and positive clone DNA digested with Asc I, 
Dra I, Bam HI and Nhe I for validation. Base pair sizes were determined using the 
standard molecular marker, O’ GeneRuler DNA Ladder (Thermo Fisher Scientific, MA, 
USA). 
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The PEPCKFluc (7267 bp) cassette was excised with Asc I restriction digest and ligated 
into the Asc I site of p∆24.7E4. The positive clones were identified with Asc I restriction 
digest (not shown). Figure 3.3 represents a positive pPEPCKFlucHDAd (Appendix 6.6) 
construct that was subjected to further validation with restriction digest (Table 3.3) using 
Asc I, Cla I and Pme I which was compared to an empty p∆24.7E4. The expected bands 
were present, indicating that the PEPCKFluc (7267 bp) cassette was successfully cloned 
into p∆24.7E4. Although, Pme I digest does not differentiate the clone from the empty 
vector. It was used because it is required to release the bacterial sequence during HDAd 
production. 
 
Table 3.3: Expected bands sizes for pPEPCKFlucHDAd following restriction digest 
Plasmid type Enzyme Type Expected base pair sizes 
p∆24.7E4 
Asc I 27459 bp 
Cla I 20065 bp and 7394 bp 
Pme I 30303 bp and 2949 bp 
pPEPCKFlucHDAd 
Asc I 27465 bp, 7267bp 
Cla I 20450 bp, 7394 bp and 6228 bp 
Pme I 31783 bp and 2949 bp 
Fragments in blue migrate close together 
 
Figure 3.3: Validation of HDAd positive clone carrying the PEPCKFluc cassette.  
Agarose gel of the positive pPEPCKFlucHDAd clone and empty pΔ24.7E4 plasmid 
validated with Asc I, Pme I and Cla I digestion, with the O’ GeneRuler DNA Ladder 
(Thermo Fisher Scientific, MA, USA). 
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Construction of anti-HBV sequence bearing HDAd plasmids 
 
Anti-HBV pri-miR 31/5 and pri-miR 31/589 sequences were previously cloned 
downstream of the PEPCK promoter in our lab to generate pLPBL31/5 and pLPBL31/589 
(Table 2.4, unpublished). HDAd vectors expressing the anti-HBV pri-miR 31/5 and pri-
miR 31/589 from a PEPCK promoter were constructed by excising the PEPCKpri-
miR31/5 and PEPCKpri-miR31/589 cassettes from  pLPBL31/5 and pLPBL31/589 using 
Asc I restriction and cloned into the  p∆24.7E4 Asc I site to generate pPEPCK31/5HDAd 
(Appendix 6.6) and pPEPCK31/589HDAd (Appendix 6.6), respectively. Clones positive 
for the insert were confirmed with Asc I restriction digest (not shown). Figure 3.4 
illustrates the confirmation of a pPEPCK31/5HDAd construct with the PEPCKpri-
miR31/5 insert. Restriction digests were performed with Asc I, Cla I and Pme I and 
compared to an empty p∆24.7E4. The expected bands as illustrated in Table 3.4 were 
present except for the bands of slight base pair difference due to the bands migrating 
together (indicated in blue). This confirmed the successful cloning of PEPCKpri-miR31/5 
into p∆24.7E4.  
 
Table 3.4: Expected bands sizes for pPEPCK31/5HDAd after restriction digest 
Plasmid Enzyme Expected base pair sizes 
p∆24.7E4 
Asc I 27459 bp 
Cla I 20065 bp and 7394 bp 
Pme I 30303 bp and 2949 bp 
pPEPCK31/5HDAd 
Asc I 27465 bp and 5784bp 
Cla I 18864 bp, 7394 bp, 6228bp and 763 bp 
Pme I 30262 bp and 2949 bp 
Fragments in blue migrate close together 
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Figure 3.4: Validation of positive HDAd clone carrying the PEPCKpri-miR31/5 
cassette.  
1 % Agarose gel of the empty p∆24.7E4 and positive clone was validated with Asc I, Pme 
I and Cla I digestion. Band sizes were determined with standard molecular weight marker; 
O’ GeneRuler DNA Ladder (Thermo Fisher Scientific, MA, USA). 
 
Figure 3.5 shows the confirmation of pPEPCK31/589HDAd construct with the PEPCKpri-
miR31/589 insert using Asc I, Cla I and Pme I and compared to an empty p∆24.7E4. The 
expected bands indicated in Table 3.5 were visible, however bands that migrate close 
together could not be differentiate (indicated in blue). The banding pattern thereby 
demonstrates the successful construction of pPEPCK31/589HDAd. 
 
Table 3.5: Expected bands sizes for pPEPCK31/589HDAd after restriction digest 
Plasmid type Enzyme Type Expected base pair sizes 
p∆24.7E4 
Asc I 27459 bp 
Cla I 20065 bp and 7394 bp 
Pme I 30303 bp and 2949 bp 
pPEPCK31/589HDAd 
Asc I 27465 bp and 6097 bp 
Cla I 
18847 bp, 7394 bp, 6228 bp and 1093 
bp 
Pme I 30613 bp and 2949 bp 
Fragments in blue migrate close together 
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Figure 3.5: Validation of the HDAd clone carrying the PEPCKpri-miR31/589 
cassette.  
1 % Agarose gel of the standard molecular O’ GeneRuler DNA Ladder (Thermo Fisher 
Scientific, MA, USA) and the positive clone and empty pΔ24.7E4 plasmid validated with 
Asc I, Pme I and Cla I restriction digestion.  
 
3.2 Anti-HBV Helper Dependent Adenoviral vector production 
 
3.2.1 Amplification of AdNG163Cys Helper virus 
 
One of the limitations for efficient and safe delivery of transgenes, is the activation of the 
host innate immune response to the adenoviral viral capsid proteins (Crowther et al., 2008, 
Croyle et al., 2005, O'Riordan et al., 1999, Yang et al., 1995). To prevent activation of the 
host innate immune response to viral capsid proteins, PEGylation can be performed. The 
introduction of cysteine residues into the hypervariable region 5 of the hexon proteins 
have shown to aid in a more specific thiol reactive PEGylation (Prill et al., 2011). This 
type of PEGylation results in a more uniform viral particle size and had less interference 
with intercellular trafficking. To enable production and propagation of HDAd vectors with 
cysteine modification, a plasmid carrying a helper virus (AdNG163Cys) genome with 
cysteine modification within the HVR 5 was donated by Philip Ng (Baylor college of 
Education, USA). This plasmid was previously used to produce AdNG163Cys. In this 
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study, AdNG163Cys was amplified and used for HDAd production and amplification. 
Successful amplification was determined by immunostaining of the infected cells. The 
infected cells are represented by the dark brown stained cells in Figure 3.6. Despite the 
successful production and amplification of this helper virus, infection of HEK293T cells 
showed consistent uneven distribution of positively stained cells, with brown cells always 
together (Figure 3.6). This made it difficult to determine accurate viral infectious units. 
Therefore, qPCR was used to determine total viral particles and 4.88 × 1010 vps in 20 ml 
were obtained, which were enough to use for HDAd production and amplification.  
 
 
Figure 3.6: Immunostaining of HEK293T cells infected with produced AdNG163Cys.  
Immunostaining was performed on both uninfected and infected HEK293T cells. The 
HEK293T cells were infected with different dilutions of AdNG163Cys followed with a 48 
hour incubation period and immunocytochemical staining to quantify the produced HV. 
All microscopic images were taken at 10× magnification. Image taken from cells infected 
with undiluted AdNG163Cys was used as a representative. AdNG163Cys infected cell 
clumping is indicated by the arrows. 
 
3.2.2 AdNG163Cys does not serve as an effective HV for HDAd propagation  
 
Because of the difficulty in determining AdNG163Cys infectious units, total viral particles 
were used to determine the amount of HV required for different MOIs tested for HDAd 
production. Interestingly, application of this helper virus in the production of β-
galactosidase expressing HDAd, resulted in an HDAd vector that bears similar signs of 
possible viral aggregation before or during infection of cells. This was indicated by 
clumped blue cells after X-gal staining in Figure 3.7. In addition, HDAd could only be 
produced with AdNG163Cys when a higher MOI of 50 was used. Amplification of this 
HDAd with AdNG163Cys at different MOIs was also unsuccessful (data not shown). 
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Figure 3.7: X-gal staining of 116 cells infected with Δ28E4CMVlacZCys.  
X-gal staining was performed on both uninfected and infected 116 cells. The 116 cells 
were infected with different dilutions of Δ28E4CMVlacZCys and incubated for 48 hours 
before X-gal staining. Image taken from cells infected with undiluted HDAd sample was 
used as a representative.   
 
To confirm if the aggregation of the virus is as a result of the cysteine modification, a 
previously produced AdNG163 helper virus with wild type HVR 5 was used to infect cells 
followed by the immunostaining. Unlike with AdNG163Cys, single brown stained cells 
were visible and could be counted to accurately determine the infectious units (Figure 3.8). 
When the AdNG163 virus was used, HDAd could be successfully produced at AdNG163 
MOI 5 (determined using total viral particles). After X-gal staining of cells with 
Δ28E4CMVlacZ produced with AdNG163, single blue cells were observed and could be 
counted to determine infectious units (Figure 3.9). The observed clumping of infected 
cells and failure of AdNG163Cys to effectively serve as helper virus for HDAd 
amplification suggest that the cysteine capsid modification may alter the capsid structure 
and affect HV infection efficiency. 
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Figure 3.8: Immunostaining of HEK293T cells infected with AdNG163 Helper virus.  
Immunostaining was performed on both uninfected and AdNG163 infected HEK293T 
cells to determine if aggregation occurs. Briefly, HEK293T cells were infected with 
different dilutions of the helper virus and incubated for 48 hours at 37 ˚C before 
immunocytochemical staining. All imaging was performed at 10 ×  magnification. 
Positively stained cells are presented by the darker brown cells indicated by the arrows. 
Image taken from cells infected with 10-5 AdNG163 dilution was used as representative. 
 
 
Figure 3.9: X-gal staining of Δ28E4CMVlacZ produced with AdNG163 helper virus.  
X-gal staining was performed on both uninfected and infected 116 cells to confirm 
whether aggregation occurs. Briefly, 116 cells were infected with different dilutions of 
Δ28E4CMVlacZ and incubated for 48 hours at 37 ˚C before X-gal staining. Ten times 
magnification was used for the imaging of the cells infected with undiluted 
Δ28E4CMVlacZ virus. Positively stained cells are presented by the blue cells indicated by 
the arrows. 
 
3.2.3 AdNG163Cys has a distorted particle structure 
 
To determine whether the aggregation and unsuccessful amplification of HDAd using 
AdNG163Cys was as a result of capsid structure modification, Transmission Electron 
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Microscopy (TEM) was performed. The TEM images presented in Figure 3.10d showed 
morphological deformation of the cysteine modified AdNG163Cys helper virus when 
compared to the unmodified AdNG163 helper virus (Figure 3.10b). The AdNG163 helper 
virus diameter was between 70-80 nm and showed the expected icosahedral shape. When 
comparing the AdNG163Cys helper virus the particle morphology was deformed, with the 
icosahedral shape lost. This suggests that the cysteine modification influenced the helper 
virus shape and structure. Confirming the X-gal staining data with Δ28E4CMVlacZCys, 
this virus showed similar structural deformities to the AdNG163Cys (Figure 3.10c) as 
compared to Δ28E4CMVlacZ (Figure 3.10a). In addition all imaging of AdNG163 and 
HDAd was of large scale productions, which is not the case for AdNG163Cys and 
HDAdCys. Due to the low HV efficiency of AdNG163Cys large scale production of 
HDAdCys could not be performed. 
 
Figure 3.10: Transmission Electron microscopy of Cysteine modified AdNG163Cys/ 
HDAdCys and unmodified AdNG163/HDAd.  
The samples were added to 0.25 % formvar-coated 300 mesh copper grids and incubated 
for 5 minutes. The grids coated with the samples were then stained with 4 % aqueous 
uranyl acetate for 5 minutes and dried overnight at room temperature.  The samples were 
viewed at 80kV on a FEI BioTwin Spirit TEM. A) HDAd virus prepared with AdNG163 
helper virus measured at 200 nm, B) AdNG163 virus measured at 200 nm C) HDAd virus 
prepared with AdNG163Cys helper virus measured at 200 nm, and D) AdNG163Cys 
helper virus measured at 200 nm. Red arrows indicating the viral particles. 
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3.2.4 Cysteine modification on the HVR 5 alters AdNG163Cys helper virus 
infection efficiency 
 
Upon infection and viral gene expression, adenoviruses such as a helper virus (E1 
deficient Ad vector) effect morphological change in the cultured cells mainly 
characterized by rounding of infected cells called cytopathic effect (CPE). This was taken 
advantage of to determine if the cysteine modification and deformities of the 
AdNG163Cys influenced the infection efficiency of the helper virus. The infection 
efficiency was determined by infecting 116 cells with AdNG163 and AdNG163Cys helper 
virus at an MOI of 2 (determined from total viral particles for both HVs). The cells were 
viewed for CPE after 48 hours. The comparison between the cysteine modified 
AdNG163Cys and unmodified AdNG163 helper viruses presented a clear difference 
between the CPE induced by the two helper viruses (Figure 3.11). Cytopathic effect of 90-
100 % was observed for AdNG163 after 48 hours. However, AdNG163Cys presented 
little or no cytopathic effect after 48 hours. The findings indicated that the cysteine 
modification of the viral capsid and the deformities of the AdNG163Cys influenced the 
infection activity of the AdNG163Cys helper virus. 
 
 
Figure 3.11: Cytopathic effect of AdNG163 and AdNG163Cys.  
116 cells were infected with both AdNG163 and AdNG163Cys at a MOI of 2, 
respectively. The cytopathic effect of both helper viruses were viewed after 48 hours at 
10× magnification. 
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3.2.5 Successful production and amplification of HDAds with unmodified 
AdNG163 helper virus 
 
As a result of deformities and reduced infection efficiency associated with cysteine 
introduction into the AdNG163 capsid, an unmodified AdNG163 was therefore used for 
all viral productions and propagations in this study. As a result of the absence of a lac Z 
reporter gene in the designed HDAd constructs, a HDAd carrying the lac Z gene was 
produced and amplified in parallel and subjected to X-gal staining to determine the 
number of infectious units. HDAd viral production consisted of three steps; rescue, 
amplification and large scale production. The rescue step required the conversion of the 
HDAd plasmid into an HDAd virus. Successful rescue of the different HDAd plasmids 
were achieved with the production of about 3.160 ×  104 infectious particles/ml. The 
produced viral particles were subjected to further passaging known as amplification to 
increase the amount of virus that was produced. Each passaging of the HDAd bearing a 
lac Z reporter gene was subjected to X-gal staining to confirm successful amplification. 
Figure 3.12, shows that an increase in the amount of positively stained cell (blue cells) 
occurred with each passage.  
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Figure 3.12: X-gal staining to monitor the amplification of the HDAd constructs.  
Amplification was performed in 116 cells with Δ28E4CMVlacZ in parallel to determine if 
the amplifications were successful. The 116 cells were infected with dilutions of the 
lysates and incubated for 48 hours, followed by X-gal staining. All microscopic images 
were captured at 10× magnification. 
 
A fold increase of between 1 and 186 in the number of infectious units was observed 
during amplification until maximum viral titers were achieved (Table 3.6). Passage 5 and 
6 indicated that optimal titers were achieved in the 60 mm plates, which could be seen by 
the slight difference in the viral titers obtained for both passages. Once optimum titers 
were achieved, the lowest passage with the highest amount of HDAd virus was used for 
amplification in 150 mm plates. Due to the slight difference in the infectious units 
obtained between passage 5 and 6, passage 5 was used for the amplification in 150 mm 
plates. The amplification resulted in a 1 fold increase in the amount of HDAd virus 
produced, yielding 4.260 × 109 ifu/ml, which was in the desired range for large scale 
production. The HDAd virus (passage 6) produced in the 150 mm plate was then used to 
co-infect cells with AdNG163 at MOI 2 and amplified in a 3 L suspension culture, 
followed by viral purification using a CsCl step gradient. A single band was observed after 
all CsCl gradient steps (Figure 3.13).  
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Table 3.6: Infectious units and fold changes obtained for each passage during HDAd 
amplification  
Passages Plate size 
Infections units/ml 
(ifu/ml) 
Fold change 
HDAd Rescue (Passage 0) 60 mm 3.160 × 104  
Passage 1 60 mm 4.420 × 105 ~ 14 
Passage 2 60 mm 1.864 × 106 ~ 4 
Passage 3 60 mm 6.630 × 106 ~ 3.5 
Passage 4 60 mm 1.960 × 107 ~ 3 
Passage 5 60 mm 3.650 × 109 ~ 186 
Passage 6 60 mm 3.790 × 109 ~ 1 
Large Scale (Passage 6) 150 mm 4.260 × 109 ~ 1 
 
 
 
Figure 3.13: A representative of a CsCl step and continuous gradients of a purified 
HDAd virus. 
A) CsCl step gradient with purified HDAd virus indicated by the arrow. B) CsCl 
continuous gradient with purified HDAd virus (indicated by arrow). 
 
The HDAd24.7E4, PEPCK31/5HDAd, PEPCK31/589HDAd and PEPCKFlucHDAd were 
successfully produced and purified in large scale. The viral titers of each CsCl gradient 
purified vector was quantified with qPCR and varied between ~ 1011 and 1013 total viral 
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particles as presented in Table 3.7 (~ 1011 and 1012 viral particles per ml). The helper virus 
contamination was quantified routinely and ranged between 0.07 % and 1 % after CsCl 
gradient purification, which was within the acceptable range. 
 
Table 3.7: Viral quantification of CsCl purified HDAd viruses 
 
3.3 Efficient expression of Firefly luciferase from PEPCK promoter by 
HDAds 
 
A problem that is often faced in gene therapy is the expression of therapeutic transgenes in 
the untargeted tissue. Owing to HBV infecting the liver, optimal expression of the 
therapeutic transgene (anti-HBV sequences) within the liver is required for sufficient HBV 
silencing. The use of liver specific Pol II promoters have shown to improve the expression 
of anti-HBV sequences and lead to the silencing of HBV gene expression (Ivacik et al., 
2015, Mowa et al., 2014). Although liver-specific promoters have been tested in our 
laboratory for expression of anti-HBV sequences, the use of the highly efficient liver 
specific PEPCK has not been investigated.  
To determine the activity of PEPCK promoter in liver derived cells in our hands, 
PEPCKFlucHDAd vector expressing Firefly luciferase from a PEPCK promoter was 
constructed and tested in Huh 7 cells. Briefly, Huh 7 cells were infected with 
PEPCKFlucHDAd or HDAd24.7E4 at an MOI of 2000. After 72 hours, cell lysates were 
used to measure luciferase activity using luciferase assay. A significant expression of 
Firefly luciferase was observed (p = 0.0045) relative to the empty HDAd vector (Figure 
3.14). The findings suggest that PEPCK promoter is efficiently active in liver derived 
cells.  
HDAd 
Total viral particles 
(VPs) 
Helper virus 
contamination ( %) 
HDAd empty vector 1.078 × 1013 0.07 % 
PEPCK31/5HDAd 2.840 × 1012 1 % 
PEPCK31/589HDAd 3.870 × 1011 1 % 
PEPCKFlucHDAd 5.385 × 1012 0.5 % 
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Figure 3.14: In vitro Firefly luciferase expression under the control of a PEPCK 
promoter.  
Huh 7 cells were infected with PEPCKFlucHDAd or HDAd24.7E4 (negative control) at a 
MOI of 2000. Luciferase reporter assay was performed 72 hours after infection. ** 
indicate significant Fluc gene expression, p = 0.0045, T-Test, two tailed, paired. Error bar 
indicates the normalized Standard error of the mean (SEM) (n=4). 
 
To validate the liver specific gene expression of Firefly luciferase from PEPCK promoter, 
HBV transgenic mice were injected with 1 ×  1010 vps of PEPCKFlucHDAd or 
HDAd24.7E4. All mice were administered with luciferase substrate D-luciferin 
intraperitoneally at 3 days, 14 days (2 weeks) and 28 days (4 weeks) post infection and 
bioluminescence was measured. Bioluminescence from 60 seconds exposure was 
quantified using the Living Image® software (Figure 3.15b). After 3 days, luminescence 
at 2.75 ×  105 relative light units was measured. After two weeks post infection, 
luminescence within the livers had significantly increased (p= 0.0495) to 1.31 ×  106 
relative light units. This was maintained at 28 days post infection (period of experiment). 
As expected, bioluminescence was not detected with saline and HDAd24.7E4 infected 
mice (Figure 3.15a). The results therefore indicated that the PEPCK promoter was capable 
of driving a sustained Firefly luciferase expression within the mice livers.  
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Figure 3.15: Bioluminescence imaging of HBV transgenic mice injected with 
PEPCKFlucHDAd. 
Mice injected with saline or HDAd24.7E4 or PEPCKFlucHDAd was injected with D-
luciferin. Bioluminescence imaging at 60 seconds was performed on 3, 14 and 28 days 
post infection. A) Bioluminescence of mice at 60 seconds exposure. B) Bioluminescence 
was quantified using the Living Image® software. * Significant increase (p<0.05), T-Test, 
two tailed, paired. Errors bar indicate the normalized Standard error of the mean (SEM) 
(n=4). 
 
CHAPTER 3  MSc Dissertation 2017 
73 | P a g e  
 
 
3.4 Assessment of HBV gene silencing by anti-HBV pri-miR’s in vitro 
 
The high in vivo and in vitro expression levels observed with Firefly luciferase expressed 
from the PEPCK promoter, prompted the investigation into applying the PEPCK promoter 
for HBV silencing through the expression of anti-HBV pri-miR sequences. The HBsAg is 
a surface glycoprotein, which is produced in excess and secreted by HBV infected liver 
cells. The HBsAg therefore offers as a good marker for active HBV infection and in turn 
for HBV gene expression. Hence, HBV knockdown was determined by measuring the 
reduction of HBsAg secretion using ELISA in Huh 7 cells transfected with pCH-9/3091 
target plasmid and infected with HDAd24.7E4 or PEPCK31/5HDAd or 
PEPCK31/589HDAd. After 48 hours, HBV knockdown by PEPCK31/5HDAd and 
PEPCK31/589HDAd was determined relative to HDAd24.7E4 as a negative control. 
 
Previous studies have shown that MOI of 500 to 1000 are enough to cause significant 
HBV replication inhibition (Mowa et al. 2014). Hence, HBV gene expression knockdown 
was first performed at a MOI 1000. At this MOI a significant HBsAg knockdown (p<0.01) 
was observed. However, it was only about 9 % for both PEPCK31/5HDAd and 
PEPCK31/589HDAd, which was less than observed in previous studies conducted with 
anti-HBV pri-miR sequences (Figure 3.16a). To determine whether the low levels of HBV 
expression knockdown was as a result of the inefficient processing and expression of the 
anti-HBV pri-miR sequences. Northern blotting was performed with RNA isolated from 
Huh 7 cells infected with PEPCK31/5HDAD or PEPCK31/589HDAD at MOI of a 1000 
(Figure 3.16b). RNA isolated from Huh 7 cells infected with HDAd expressing pri-miR 
31/589 from MTTR promoter at an MOI of 1000 was used as a positive control. After 
hybridisation with probes specific for guide 5, 8 and 9, a 21 nt band was detected with the 
positive control. Guide 5 probe also showed a higher molecular weight band representing 
unprocessed or partially processed intermediates. However, the guide sequences were not 
detectable in the RNA samples for the anti-HBV pri-miR sequences expressed from a 
PEPCK promoter, indicating inefficient expression of the anti-HBV pri-miRs. This 
analysis revealed that the PEPCK promoter could not efficiently express the anti-HBV pri-
miR sequences. 
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Figure 3.16. In vitro analysis of HBV knockdown and expression of anti-HBV pri-
miR sequences. 
A) Huh 7 cells were transfected with pCH-9/3091 and infected 5 hours later with 
HDAd24.7E4 or PEPCK31/5HDAd or PEPCK31/589HDAd at MOI 1000. Supernatant 
was collected after 48 hours and ELISA was performed to determine HBV knockdown by 
reduction in HBsAg concentration. PEPCK31/5HDAd and PEPCK31/589HDAd was 
normalized to HDAd24.7E4. ** Significant (p<0.01), T-Test, two tailed, unpaired. Error 
bars represented as Standard error of the mean (SEM) (n=4). B) In vitro Northern blot 
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analysis of 30µg of RNA extracted from Huh 7 cells infected with HDAd24.7E4 or 
PEPCK31/5HDAd or PEPCK31/589HDAd at a MOI of 1000. Probing was performed 
with probes complementary to guide 5, -8 and -9. Equal loading of wells was determined 
by the visualization of the RNA after Ethidium bromide staining. 
 
To determine which MOI will result in enough pri-miR expression and HBV gene 
silencing HBsAg ELISA and Dual Luciferase assay were performed at different MOIs. A 
dose-dependent reduction between 10 % and 40 % in the HBsAg secretion levels were 
observed (Figure 3.17). The higher and significant reduction (p<0.01) of HBsAg 
expression HBsAg at an MOI of 20000 was observed with PEPCK31/589HDAd. This 
indicated that PEPCK31/589HDAd was more effective in HBV silencing compared to 
PEPCK31/5HDAd. However, the HBV knockdown was non-significant (p>0.05) for 
remainder of the MOI’s 2000 and 10000 for PEPCK31/5HDAd and PEPCK31/589HDAd. 
Based on these observations and compared to previous studies (Mowa et al., 2012, Mowa 
et al., 2014), a high amount of virus is required to obtain a higher and significant level of 
HBV knockdown by the anti-HBV pri-miR’s expressed from PEPCK promoter. This 
suggests that anti-HBV pri-miR expression was too low to be detected on a northern blot 
analysis when MOI 1000 was used.  
 
To validate the results obtained with ELISA, Dual luciferase reporter assay was 
performed. The psiCHECK-HBx plasmid, which contains the HBx sequence downstream 
of the Renilla luciferase ORF was used. This renders the Renilla luciferase susceptible to 
silencing by anti-HBx sequences such as pri-miR, while the Firefly luciferase expression 
remains unaffected. Therefore, HBV knockdown is determined by the ratio of Renilla 
luciferase to Firefly luciferase. This entailed the transfection of Huh 7 cells with 
psiCHECK-HBx, followed by infection with HDAd24.7E4 (negative control) or 
PEPCK31/5HDAd or PEPCK31/589HDAd at the same MOI’s of 2000, 10000 and 20000. 
Cell lysates were then used for luciferase assay. To determine HBV knockdown, the ratio 
of Renilla luciferase expression to Firefly luciferase expression for PEPCK31/5HDAd and 
PEPCK31/589HDAd was normalized to HDAd24.7E4 ratios. 
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Figure 3.17: Assessment of HBV knockdown by anti-HBV pri-miR by ELISA.  
Huh 7 cells were transfected with pCH-9/3091. After 5 hours the cells were infected with 
HDAd24.7E4 or PEPCK31/5HDAd or PEPCK31/589HDAd at MOI’s of 2000, 10000 and 
20000. Supernatant was collected after 48 hours and ELISA was performed to determine 
HBV knockdown by reduction in HBsAg concentration. The PEPCK31/5HDAd and 
PEPCK31/589HDAd was normalized to HDAd24.7E4. ** Significant (p<0.01), ns – Non-
significant (p>0.05), T-Test, two tailed, unpaired. Error bars represented as Standard error 
of the mean (SEM) (n=4). 
 
Similar to ELISA, a reduction in HBV expression between 10 % and 50 % was obtained 
for both PEPCK31/5HDAd and PEPCK31/589HDAd at the different MOI’s (Figure 3.18). 
A significant (p<0.05) decrease was observed at MOI 2000 and 20000 for 
PEPCK31/589HDAd, which had a greater percentage of HBV silencing compared to 
PEPCK31/5HDAd. Non-significant (p>0.05) reduction at the remainder of the MOI’s for 
both PEPCK31/589HDAd and PEPCK31/5HDAd was observed. The highest MOI of 
20000 caused the greatest decrease in HBV expression, again confirming the requirement 
of a higher MOI for effective HBV replication inhibition by these HDAds.  
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Figure 3.18: Dual luciferase reporter assay to determine HBV knockdown by anti-
HBV pri-miR. 
Huh 7 cells were transfected with psiCHECK-HBx. Five hours after transfection, the cells 
were infected with HDAd24.7E4 or PEPCK31/5HDAd or PEPCK31/589HDAd at MOI of 
2000, 10000 and 20000. Cells were harvested in lysis buffer after 48 hours and Dual 
Luciferase reporter assay was performed to determine HBV knockdown as a ratio of 
Renilla luciferase:Firefly luciferase. PEPCK31/5HDAd and PEPCK31/589HDAd were 
normalized to HDAd24.7E4. * Significant (p<0.05), ns – Non-significant (p>0.05), T-
Test, two tailed, unpaired. Error bars represented as Standard error of the mean (SEM) 
(n=4). 
 
3.5 Assessment of pri-miR expression and HBV knockdown in vivo  
 
Previous studies have shown a high PEPCK promoter driven transgene expression from 
HDAds in vivo (Brunetti-Pierri et al., 2006, Mian et al., 2004). To determine if PEPCK 
promoter is stronger in vivo than in vitro, mice studies were performed. As 
PEPCK31/589HDAd showed better effect against HBV in vitro, it was used to assess the 
inhibition of HBV replication in mice. HBsAg levels were measured in mice injected with 
saline or 1 ×  1010 vps of HDAd24.7E4 or PEPCK31/589HDAd. Blood serum was 
collected one week and two weeks after injection and ELISA was performed to determine 
HBV knockdown relative to the control HDAd24.7E4. However, there was no HBsAg 
levels reduction observed after both one week and two weeks. This observation showed 
that there was no significant reduction in the in vivo HBV replication inhibition by the 
anti-HBV pri-miR HDAd (Figure 3.19a). This was supported by lack of anti-HBV pri-miR 
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expression after one week injection of PEPCK31/589HDAd and Northern blot analysis 
(Figure 3.19b).  
 
These observations could be as a result of ineffective liver transduction by the HDAd viral 
particles or induction of a strong immune response that lead to early vector clearance.  
 
3.6 Liver transduction by HDAd vectors expressing anti-HBV pri-miR  
 
To determine if hepatocyte transduction was achieved, viral particle equivalents were 
measured in HDAd infected mice livers by qPCR (Figure 3.20). Mice livers were 
harvested one week post-injection with saline or 1 ×  1010 vps of HDAd24.7E4 or 
PEPCK31/589HDAd. DNA extracted from the livers was used for qPCR with primers 
specific for HDAd. As expected, the results showed that mice administered with saline had 
no HDAd viral particles present. On the other hand, the mice subjected to HDAd24.7E4 or 
PEPCK31/589HDAd infection showed the presence of HDAd viral particles between 2 to 
3 ×  105 VPEs/µg DNA. Thus, efficient delivery of HDAd24.7E4 and 
PEPCK31/589HDAd viral particles to hepatocytes was achieved. Meaning that the 
therapeutic HDAd viral particles transduced the liver effectively and compared to previous 
study (Mowa et al., 2014) HDAd present within the livers was enough to result in a 
significant HBV knockdown.   
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Figure 3.19: Assessment of in vivo knockdown of HBV replication and anti-HBV pri-
miR expression from a PEPCK promoter.  
The mice were administered separately with Saline or 1 × 1010 vps of HDAd24.7E4 or 
PEPCK31/589HDAd through tail vein injection. A) Blood serum was collected through 
retro-orbital puncturing before injection one week and two weeks after injection and 
ELISA was performed. Knockdown of HBV gene expression by PEPCK31/589HDAd was 
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determined relative to the control virus HDAd24.7E4. T-test, unpaired, two-tailed, ns- 
non-significant Error bar presents as standard error of the mean (n=6). B) Liver infected 
with HDAd24.7E4 or PEPCK31/589HDAd were harvested and 30 µg of RNA was 
analysed and probed with oligonucleotides complementary to guide 5, 8 and 9. RNA from 
Huh 7 cells infected with HDAd expressing pri-miR 31/589 from MTTR promoter at MOI 
of 100 was used as a Northern blot control. Equal loading of wells were determined by the 
visualization of RNA after Ethidium bromide staining. 
 
 
Figure 3.20: Intrahepatic HDAd viral particle levels.  
HBV transgenic mice were injected with saline or 1 ×  1010 vps of HDAd24.7E4 or 
PEPCK31/589HDAd. One week post-infection, DNA was extracted from the infected 
livers and qPCR was performed with HDAd specific primers. Error bars represented as 
standard error of the mean (SEM) (n=4).  
 
3.7 HDAd viral particles did not induce a pronounced inflammatory 
response or liver toxicity  
 
To determine if HDAds administered induced a strong acute inflammatory response that 
may result in toxicity and vector clearance, levels of secreted pro-inflammatory cytokines 
and liver toxicity marker Alanine Aminotransferase (ALT) were measured. IL-12p70, 
IFN-γ, TNF, MCP-1, IL-10 and IL-6 levels were measured at 0, 6 and 24 hours after the 
administration of saline or 1 × 1010 HDAd particles in mice using CBA assay. Poly (I:C) 
was used as a positive control and mice were euthanized after 6 hours due to high toxicity 
induced by this RNA. Mice injected with Poly (I:C) showed a significant (*P<0.05 and 
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**P<0.01) elevation of TNF, MCP-1, IL-10 and IL-6 but not for IL-12p70 and IFN-γ after 
6 hours. In the contrary, out of all the cytokines measured only MCP-1 and IL-12p70 
levels were elevated when compared to saline control for PEPCK31/589HDAd and 
HDAd24.7E4   after 6 hours respectively. However, MCP-1 and IL-12p70 increase was 
not statistically significant (p>0.05) and both cytokines were back to normal levels at 24 
hours post infection (Figure 3.21a,b). Therefore, no concerning inflammation was induced 
by the HDAds.  
 
A) 
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Figure 3.21: CBA analysis after HDAd viral particle administration.  
The single dose of saline, Poly (I:C) or 1 ×  1010 vp of HDAd24.7E4 and 
PEPCK31/589HDAd was administered to HBV transgenic mice. Blood was collected 
through retro-orbital puncturing at 0, 6 and 24 hours after injection. The pro-inflammatory 
cytokines; IL-12p70, IFN-γ, TNF, MCP-1, IL-10 and IL-6 were measured with the CBA 
assay. A) Representation dot plot from CBA, PE-A - Phycoerythrin conjugate and APC-A 
– Allophycocyanin conjugate. B) Serum cytokine concentrations. Serum cytokine 
concentrations were determined relative to saline for that time point. T-test, two-tailed, 
unpaired, * significant (p<0.05), ** significant (p<0.01). Error bars represented as 
standard error of the mean (SEM) (n=5).  
 
The hepatotoxicity of HDAd vectors were determined by measuring ALT levels present in 
the liver as a marker of toxicity (Figure 3.22). Serum from blood collected from the mice 
at 3 days, 7 days and 14 days after HDAd administration was used. The ALT levels varied 
between 25 - 44 U/L for all the groups over 14 days. These ALT levels were within the 
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acceptable level of 100 U/L. Lack of hepatotoxicity was confirmed by normal weight 
maintained by all the mice over the period of the experiment (Figure 3.23). 
 
Figure 3.22: Alanine Transaminase activity after HDAd vector administration.  
Mice were injected with Saline or 1 × 1010 vps of HDAd24.7E4 or PEPCK31/589HDAd. 
Blood serum was collected and ALT levels were measured at 0 days, 3 days, 7 days and 
14 days. Error bars represented as standard error of the mean (SEM) (n=6). Dotted line 
indicates acceptable range for ALT levels of up to 100 (U/L).    
 
 
Figure 3.23: Line graph representing the weights of the mice.  
Mice were weighed before and weekly post-infection with Saline or HDAd24.7E4 or 
PEPCK31/589HDAd. 
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CHAPTER 4 
 
4 DISCUSSION 
 
Hepatitis B is a global health problem that infects approximately 2 billion people 
worldwide of which 240 million are chronic cases. The discovery of effective therapies 
against HBV infection is key to reducing the spread of this condition. The exploitation of 
the RNAi pathway for the sequence specific silencing of genes is well established as a 
research tool in gene therapy (Elbashir et al., 2001, McBride et al., 2008, McCaffrey et al., 
2003, Peng et al., 2005). Studies have shown the successful therapeutic application of the 
RNAi technology (RNAi activators) for the treatment of serious viral diseases. Harnessing 
of RNAi to inhibit HBV replication has shown a lot of promise. (Peng et al., 2005, Gitlin 
et al., 2002, Hamasaki et al., 2003, Jacque et al., 2002, Lee et al., 2002, Wilson et al., 
2003). RNAi activators such as monocistronic (pri-miR 31/5 and pri-miR 122/5) and 
trimeric (pri-miR31/589) anti-viral expression cassettes have successfully been designed 
within AGTRU. These anti-viral expression cassettes, expressing anti-HBV pri-miR from 
Pol II promoters have shown to be successful against HBV (Ely et al., 2009, Ivacik et al., 
2015, Mowa et al., 2012, Mowa et al., 2014). 
 
The lack of safe, efficient delivery and expression system for these anti-HBV pri-miR’s 
are one of the obstacles that needs to be overcome before these RNAi effectors can reach 
clinical application. This study therefore focused on obtaining efficient, tissue specific 
expression and a safer delivery system for anti-HBV RNAi activators. 
 
4.1.1 Successful Construction of lac Z deficient HDAd genome plasmids 
carrying PEPCK-pri-miR cassettes. 
 
Mowa and colleagues performed one of the first experimental studies using HDAds 
expressing anti-HBV pri-miR from a CMV promoter. These vectors transduced 90 % of 
hepatocytes and inhibited HBV replication efficiently in vivo without toxic side effects for 
1 to 5 weeks (Mowa et al., 2012). To prolong the transcription and HBV inhibition, the 
CMV promoter in the anti-HBV cassettes were replaced with a liver specific modified 
mouse transthyretin (MTTR) promoter and delivered using lentiviral vectors (LVs) or 
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HDAds (Ivacik et al., 2015, Mowa et al., 2014). Data collected indicated that LVs 
expressed the transgenes and silenced the HBV genes over a course of 1 year within the 
liver of the mice (Ivacik et al., 2015). However, in vitro and ex vivo gene delivery with 
LVs is still limited by the low titers produced during viral production (Kubo and Mitani, 
2003, Nguyen et al., 2002). Furthermore, another concern is the potential oncogene 
activation and/or tumor suppressor genes caused by LV integration into the host genome. 
As well as the pathogenicity that may be caused by the recombination and regeneration of 
the wild type virus, HIV-1 (Matrai et al., 2010, Manjunath et al., 2009). 
 
HDAds carrying anti-HBV pri-miR expressed from a liver-specific MTTR promoter 
resulted in expression and processing of designed anti-HBV pri-miRs that is more 
sustained when compared to that of the CMV promoter (Mowa et al., 2014). However, 
HBV knockdown was over a short time period and an increase in HBsAg levels were 
observed after 3 weeks for the monomeric pri-miR cassettes and after 5 weeks for the 
trimeric pri-miR cassettes (Mowa et al., 2012, Mowa et al., 2014). Improvement of these 
MTTR-pri-miR carrying HDAds is currently being investigated in our lab. The use of 
vectors bearing a PEPCK promoter has shown long-term liver specific gene expression in 
various studies (Brunetti-Pierri et al., 2007, Mian et al., 2004). Mian and colleagues 
observed the rectification of orotic aciduria with considerable OTC activity for 12 months 
(length of experiment) in the absence of chronic liver toxicity. By expressing human 
ornithine transcarbamylase (hOTC) in the presence or absence of a Woodchuck hepatitis 
virus posttranscriptional regulatory element (WPRE) from a PEPCK promoter (Mian et 
al., 2004). Brunetti-Pierri and co-workers observed long-term (> 1 year) and stable hepatic 
expression of the α-fetoprotein (bAFP) from a PEPCK promoter in non-human primates in 
the absence of chronic liver toxicity (Brunetti-Pierri et al., 2007, Brunetti-Pierri et al., 
2006). However, the application of this promoter to express RNAi activators has never 
been explored. For that reason, this study investigated the possibility of using the PEPCK 
promoter for a sustained liver specific expression of anti-HBV pri-miR mimics.  
 
To detect successful delivery and tissue transduction, reporter genes such as lac Z have 
been incorporated into delivery vectors such as FGAd and HDAd. However, an induction 
by β-galactosidase of the adaptive immune response and/or cellular immune response of 
the host results in loss of viral gene expression and destruction of transduced cells (Mian 
et al., 2005, Morral et al., 1997, Rauschhuber et al., 2008). Studies performed showed 
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similar results which presented the activation of the immune response and production of 
neutralizing antibodies against Adenoviral vectors bearing the lac Z report gene (Sullivan 
et al., 1997, Crowther et al., 2014, Mowa et al., 2014). As a result, expression of the 
transgenes were short-lived due to clearance of the Ad vectors by the activation of the 
immune response. Hence, the removal of the lac Z reporter gene from HDAd vectors 
could lengthen liver transduction and antiviral sequence expression by reducing immune 
stimulation, which in turn could prolong HBV knockdown. 
 
Because of their larger size (~ 27- 32 kb), cloning into HDAd genome carrying plasmids is 
difficult. This is as a result of difficulties to ligate into the HDAd backbone and the lower 
transformation efficiencies that are usually obtained. Hence, some studies have used 
homologous recombination between a shuttle vector carrying the transgene and an 
Adenoviral backbone in place of the conventional ligation. In this system, the shuttle 
vector is transformed into the E. coli cells containing the Ad plasmid and recombinants 
selected. This method eliminates the need for large Ad backbone manipulation by 
restriction digest and ligations (He et al., 1998, Luo et al., 2007). In addition, 
transformation efficiency can be increased by the use of highly effective transformation 
techniques like electroporation. Although the generation of lac Z deficient Helper 
Dependent Adenoviral plasmids expressing anti-HBV pri-miR’s from a liver-specific 
PEPCK promoter was challenging, the construction was successful. The constructed anti-
HBV HDAd plasmids were confirmed by multiple restriction digests and used to produce 
anti-HBV HDAds vectors.  
 
4.1.2 Cysteine modification in the Adenoviral capsid alters the particle structure 
and impairs helper virus role in HDAds production 
 
In addition to the removal of reporter genes in HDAds, immune stimulation by the viral 
capsid proteins through site specific PEGylation can be performed. To facilitate residue 
specific and thiol reactive PEGylation, cysteine residues were previously incorporated into 
the HVR5 of Ad helper virus [AdNG163Cys, (Kreppel et al., 2005, Prill et al., 2011)]. 
Hence, packaging and propagation of the HDAd genomes in capsid encoded by this helper 
virus will bear the modification in their capsid. PEGylation of Ad capsid proteins have 
shown to reduce the cytotoxicity and innate and adaptive immune response against the 
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viral proteins, thereby extending the duration of transgene expression (Croyle et al., 2001, 
Mok et al., 2005, Crowther et al., 2008). Furthermore, unlike amine reactive PEGylation, 
site specific thiol reactive PEGylation showed an increase in hepatocyte transduction, 
higher particle uniformity by allowing precise shielding at the desired sites, and a 
reduction in the amount of polymers required to shield the capsid epitopes (Kreppel et al., 
2005, Prill et al., 2011). 
 
An attempt to use AdNG163Cys HV in this study revealed interesting features of the HV 
as a result of the HVR5 cysteine modification. During the propagation of the 
AdNG163Cys helper virus, immunostaining showed the aggregation of the helper virus.  
This was confirmed by the fact that HDAd produced using the AdNG163Cys HV also 
seemed to be aggregating. Failure to amplify HDAd using this HV also suggest 
impairment in transduction. The comparison of infection efficiency between the modified 
and unmodified (AdNG163) virus confirmed that the infection efficiency of the cysteine 
modified virus was diminished, indicated by minimal cytopathic effect induced by 
AdNG163Cys (Figure 3.11). The introduction of specific genetic mutations could possibly 
bring about the misfolding of the modified viral proteins, influencing the structure of the 
viral capsid, as well as the function of resultant virus itself. TEM images (Figure 3.10) 
obtained for both cysteine modified (AdNG163Cys) and unmodified helper virus 
(AdNG1563), showed that the AdNG163 was 70-80 nm in size, icosahedral in shape and 
the intact capsids were visible. Interestingly, a distinct change in the morphology of 
AdNG163Cys was observed. The icosahedral shape could not be seen and the capsid was 
deformed. These changes suggest that the cysteine modification influenced the helper 
virus protein folding, assembly, and biological function. However, these findings were not 
in agreement with studies performed by other authors, which indicated that the structure 
and biological function of the virus with the cysteine modification at the HVR5 was not 
influenced by the capsid modification with the cysteine residues (Kreppel et al., 2005, 
Prill et al., 2011). Prill and colleagues applied this site specific PEGylation method to 
improve the delivery of Adenoviral vectors to the liver by using thiol reactive PEG, which 
react with thiol groups in cysteine residues that was introduced into the hypervariable 
region 5 (HVR 5) of the hexon protein successfully. However, they showed that certain 
single point mutation could either decrease or increase hepatocyte transduction, and 
particle uniformity (Prill et al., 2011).   
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On the other hand, Kreppel and colleagues performed the study with E1 deleted Ad5 
adenoviral vectors that have been genetically modified with cysteine residues into the H1 
loop of the Ad fiber protein. During the process of viral purification, aggregates were 
observed. Suggesting that the thiol groups formed interparticle disulphide bonds, which 
could be reduced by the addition of a reducing agent. However, aggregates could not be 
sufficiently resolved for Ads carrying one (Ad1Cys) or three (Ad3Cys) genetically 
introduced cysteine residues (Kreppel et al., 2005). With the challenge to reduce the 
aggregation that have been observed with the AdNG163Cys, HDAd production in this 
study can be attempted under reducing condition with either Dithiothreitol (DTT) or 
Tris(2-carboxyl)phosphine) [TCEP] reducing agents that could control the reactivity of the 
thiol groups. However, to overcome deformities observed in our hands by TEM, the HV 
virus used will need to be sequenced to determine the possibility of other mutation within 
the hexon gene. 
 
4.1.3 Production, propagation and activity of unmodified HDAds in vitro and in 
vivo 
 
Unlike with AdNG163cys, HDAds were produced effectively using AdNG163. Based on 
the β-galactosidase expressing vector produced in parallel, about 3.160 × 104 infectious 
viral particles were produced. This could easily be amplified to about 4.260 × 109 ifu/ml 
after five passages. These results obtained are in correlation with the findings and protocol 
by Palmer and Ng, (2008b), which indicated that optimal 108 - 109 ifu/ml could be 
obtained after production and amplification in plates. All the HDAds were successfully 
produced in a large scale production and purified with a two-step CsCl gradient. A single 
band was observed after each CsCl gradient step (Figure 3.13). Quantification by qPCR 
indicated that the total viral particles of the purified viruses varied between 1011 and 1013 
while the helper virus contaminations were routinely between 0.07 % and 1 %. The HDAd 
quantification and percentage of HV contamination was within the expected range of 1011 
to 1013 purified vector particles with HV contamination of ≤ 1 % that is normally obtained 
during large scale production that uses the Cre/loxP system (Ng et al., 2002, Palmer and 
Ng, 2008a).  
 
To test for activity of PEPCK promoter in our hands a lac Z deficient HDAd expressing 
Firefly luciferase was produced and characterised in vitro and in vivo. Experiments in both 
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Huh 7 cells and mice showed a significant expression of Firefly luciferase (Figure 3.14, 
Figure 3.15). Bioluminescence in mice illustrated sustained liver specific expression of 
Firefly luciferase over a time period of 4 weeks post infection (period of the experiment), 
with the maximum expression observed at 2 weeks post infection (Figure 3.15). Similar 
results were obtained previously where a significant Firefly luciferase gene expression 
was observed with a plasmid expressing Firefly luciferase under the control of PEPCK 
(pPEPCK-Fluc) in cancerous liver cells and non-tumorigenic liver cells (Song and Lee, 
2006). The results confirm that the PEPCK promoter is highly active in the liver. 
However, to confirm even longer sustainable expression in liver, Firefly luciferase 
expression is currently being monitored over a period longer than four weeks. 
Nevertheless, this motivated the aim to design PEPCK promoter driven pri-miR constructs 
to achieve liver specific expression and HBV replication silencing.  
 
The proven liver specificity and long-term transgene expression observed in the liver with 
the PEPCK promoter from this study and others (Brunetti-Pierri et al., 2007, Brunetti-
Pierri et al., 2006, Mian et al., 2004, Song and Lee, 2006), made it a suitable promoter for 
anti-HBV pri-miR expression and sustained HBV knockdown analysis. However, the 
HBV knockdown analysis only showed marginal HBV gene expression silencing, with 
higher quantity of HDAd (MOI 20000) required to obtain ~50 % knockdown in vitro 
(Figure 3.17 and Figure 3.18). Regardless of the low percentage of HBV inhibition, the 
trimeric pri-miR expressing HDAd demonstrated more efficient HBV silencing. This 
agrees with previous HBV knockdown studies performed by Mowa and colleagues 
whereby the trimeric pri-miR 31/589 showed a significant decrease in HBV gene 
expression over a longer period (5 weeks) compared to the monomeric pri-miR 31/5 and 
pri-miR 122/5 (Mowa et al., 2014, Mowa et al., 2012). The requirement of high dosages 
for PEPCK31/5HDAd and PEPCK31/589HDAd in culture contradicts with previous 
studies performed with anti-HBV pri-miR’s HDAd expressed from a MTTR promoter. 
The study performed showed efficient HBV replication knockdown of ~91 % at MOI’s of 
500 and 1000 in Huh 7 cells (Mowa et al., 2014). There are several possibilities that may 
result in marginal pri-miR expression and HBV gene silencing observed in this study. 
While reporter gene removal is desirable for in vivo studies, it also comes with its 
limitations. Meaning that the qPCR quantification method used does not discriminate 
between infectious and uninfectious viral particles. Similar conclusions were made by 
Crettaz et al., (2008) using the qPCR based method to determine the total viral particles in 
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the viral stock, whereby the total viral particles were ~1011 and the infectious units of the 
same viral stock was ~1010 (Crettaz et al., 2008). To improve the quantification and obtain 
a more accurate measurement of the produced infectious units of HDAds, a DNA-based 
technique known as the slot-blot assay was describe by (Kreppel et al., 2002), briefly cells 
are infected with diluted HDAd virus and incubated for 15 hours. The cells are then 
harvested and lysed. The lysates are then slot blotted onto a nylon membrane submerged 
in wash buffer. The membrane is then cross-linked and hybridized with [32P] labelled 
probes specific for the left ITR of Ad5 and probes specific for the HV. Signal from 
exposure is then measured using a phosphoimager. 
 
The other possibility could be that PEPCK promoter might not be a strong enough 
promoter to drive RNAi activator expression such that the desired HBV knockdown is 
achieved. This was supported by no expression of pri-miRs observed when RNA was 
isolated from cells infected with HDAds at MOI of 1000 (Figure 3.16b). Studies 
performed within primary hepatocytes to determine the strength of expression of different 
promoter revealed that PEPCK had a lower activity in vitro (primary hepatocytes) 
compared to viral promoters such as CMV. However, when tested in transgenic mice the 
promoter activity could be stimulated for high mRNA expression (Ponder et al., 1991). In 
addition, most of the studies that showed long-term transgene expression by the PEPCK 
promoter, were conducted in vivo (Brunetti-Pierri et al., 2006, Brunetti-Pierri et al., 2009, 
Brunetti-Pierri et al., 2007, Mian et al., 2004). We therefore speculated that PEPCK 
promoter could be highly active in vivo than in vitro. Because previous studies have shown 
that total viral particles determined by qPCR are usually about half a log to a log higher 
than infectious units (Crettaz et al., 2008), in vivo studies were performed by injecting 
mice with 1 × 1010 viral particles per mouse, which was double the standard dose of 5 × 
109 viral particles per mouse. However, the in vivo analysis of HBV knockdown showed 
no significant change in the HBV replication at 1 or 2 weeks post HDAd infection (Figure 
3.19a). Supporting the in vitro data, there was no pri-miR expression detected in mice at 
one week post infection with PEPCK31/589HDAd (Figure 3.19b).   
 
Even though expression of pri-miR at HDAd MOI of 1000 could not be detected by 
Northern as seen in previous studies (Mowa et al., 2012, Mowa et al., 2014) , a lower but 
significant HBV knockdown was observed (Figure 3.16a,b). Indicating that the PEPCK 
promoter was not efficient for the in vitro expression of pri-miR. Furthermore, the 
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complete lack of HBV gene silencing in vivo could also be explained by the nature of the 
mouse model used in this study. In our hands mice with medium HBsAg (OD 0.4 - 0.6) 
are the relevant ones and demonstrate HBV gene silencing by RNAi activators. However, 
as the majority of the transgenic pups have very high HBsAg levels (OD 0.8 - 1), which 
may not mimic the exact situation in human, these high titer mice were used. Hence, these 
experiments need to be repeated with medium HBsAg level mice. Alternatively, we 
speculated that HDAds used may not transduce the liver efficiently or induce an immune 
response that results in earlier vector clearance and toxicity. 
 
4.1.4 HDAds transduce the liver efficiently and do not induce a significant 
inflammatory response and toxicity 
 
HBVs ability to infect almost 100 % of liver hepatocytes, prompts the use of Ad vectors as 
a viable treatment method. The efficient hepatotropism of HDAd vectors have been 
proven beyond reasonable doubt (Brunetti-Pierri et al., 2012, Brunetti-Pierri and Ng, 
2011, Brunetti-Pierri et al., 2006, Mian et al., 2004, Crowther et al., 2014, Mowa et al., 
2012, Mowa et al., 2014). However, the lack of expected HBV replication inhibition by 
HDAds used in this study raised the necessity to confirm liver transduction. Transduction 
was assessed by qPCR using DNA isolated from mice liver at 1 week post infection. 
About 2 × 105 HDAd particles/µg DNA were detected in the livers (Figure 3.20). The 
VPEs obtained in this study were comparable to those obtained in the study by Mowa and 
co-workers where about 3 × 105 VPEs/µg were present in the hepatocytes at 1 week post 
infection and these gave about 90 % HBV knockdown. To determine if the removal of the 
lac Z reporter gene resulted in sustainable liver transduction (prevented or reduced the 
clearance of the therapeutic HDAd), the VPE’s will have to be measured over a longer 
time period. However, this shows that the amount of vector administered results in enough 
liver transduction to effect HBV replication inhibition.  
 
The activation of the immune response by Adenoviral vectors forms great reason for 
concern with the use of Ad vectors as a delivery system. This entails the activation of an 
acute innate inflammatory response and toxicity that is set in progress and Ad viral 
particles are cleared from the blood circulation (Brunetti-Pierri et al., 2009, Morral et al., 
1997, Schnell et al., 2001, Tomasec et al., 2007). However, HDAd vectors were generated 
CHAPTER 4  MSc Dissertation 2017 
92 | P a g e  
 
 
to minimize the immune response and toxicity that have been associated with FGAd 
vectors by the removal of all the viral genes. This aids in diminishing the long-term 
humoral and cell-mediated adaptive immunity. Nevertheless, an immune response is 
activated by the viral capsid proteins of both infectious and non-infectious viral particles 
(Crowther et al., 2008, Crowther et al., 2014, Muruve et al., 2004, Schnell et al., 2001, 
Croyle et al., 2005). Therefore, the induction of inflammation by the administered 
PEPCK31/589HDAd and empty HDAd24.7E4 was determined using the CBA assay. 
Even though not comparable to Poly (I:C) control, there was an elevation in the MCP-1 
and IL-12p70 (non-significant) in HDAd injected mice, however this returned to normal 
levels after a 24 hour period (Figure 3.21b). This finding correlates with previous studies 
performed within AGTRU, whereby HDAd vectors expressing shRNA (Crowther et al., 
2008, Crowther et al., 2014) or pri-miR (unpublished) resulted in an elevation of MCP-1 6 
hours after receiving the HDAd viral particles and reverted back to normal levels after 24 - 
48 hours post-infection.  
 
The expression of anti-HBV shRNAs have been reported to saturate the endogenous RNAi 
pathway, which results in liver toxicity (Grimm et al., 2006). To determine if anti-HBV 
pri-miR HDAd vectors would result in liver toxicity, the ALT levels were determined and 
found to be within the acceptable range of 40 - 100 U/L (Figure 3.22). This is in 
agreement with results obtained for the administration of anti-HBV pri-miR HDAd 
bearing a CMV promoter (Mowa et al., 2014). Supported by the healthy average weights 
of the mice, this data indicated that the anti-HBV pri-miR HDAds used in this study were 
not toxic to the mice (Figure 3.23).  
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CHAPTER 5 
 
5 CONCLUSION 
 
This dissertation reports the first study of the incorporation of RNAi activators into a lac Z 
deficient HDAd vector under the control of a liver-specific PEPCK promoter. Liver-
specific and sustainable gene expression from a PEPCK promoter was validated by the 
Firefly luciferase reporter gene expression in vitro and in vivo. While a PEPCK promoter 
is suitable for the expression of other genes such as Fluc, it is not adequate for RNAi 
activator expression. This work confirms that the removal of the viral genes from HDAd 
vectors markedly attenuates the immune response, which limits hepatotoxicity. Therefore, 
presenting the therapeutic potential and utility of HDAd vectors for hepatotropic delivery 
of antiviral sequences.  
 
5.1.1 Future studies 
 
To improve the expression of anti-HBV pri-miR, a different liver-specific promoter like 
MTTR could be used. Furthermore, the method of quantification will have to be optimized 
to quantify the infectious unit of the lac Z deficient HDAd viral stock, whereby a slot-blot 
method could provide a possible solution. Whether the elimination of lac Z from HDAds 
results in the reduced immune stimulation that translates to prolonged HBV gene silencing 
needs to be investigated further by performing long-term studies. This would provide 
some insight into the design of more desirable HDAd vectors. In order to reduce or 
completely eradicate the immune stimulation caused by the capsid proteins, PEGylation of 
the viral particles needs to be performed, followed by a comparison study between 
PEGylated and unPEGylated HDAd vectors.  
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CHAPTER 6 
 
6 APPENDIX 
 
6.1 Bacterial methods solutions and recipes  
 
6.1.1 Luria Bertani (LB) agar medium  
 
Ten grams of tryptone, 5 g of Yeast extract, 5 g NaCl and 10 g of agar was added to 1 L of 
distilled water. The medium was autoclaved for 20 minutes at 121 ̊C and 1 kg/cm2. The 
solution was cooled to approximately 55 ̊C and the desire antibiotic (100 µg/ml Ampicillin 
or 50 µg/ml Kanamycin) was added. The agar was poured into bacterial petri dishes and 
allowed to set over night. 
 
6.1.2 Luria Bertani (LB) Medium 
 
Ten grams of tryptone, 5 g of Yeast extract and 5 g NaCl was added to 1L of distilled 
water. The medium was autoclaved for 20 minutes at 121 ̊C and 1 kg/cm2. 
 
6.1.3 X-gal (5-bromo-4-chloro-3-indoyl-b-D-galactopyranoside) reagent 
 
Twenty milligrams of X-gal was dissolved in 1 ml of dimethyl formamide. Due to the 
light sensitivity, the solution was cover in foil and stored at -20 ̊C in a dark area. 
 
6.1.4 Ampicillin stock solution (100mg/ml) (PanReac Applichem inc., MO, USA) 
 
One gram of ampicillin was weighed out and dissolved in 5 ml of sterilized dH2O and 5 ml 
of absolute ethanol (100 %). The solution was filter sterilized and stored at -20 ̊C. 
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6.1.5 Kanamycin stock solution (50mg/ml) (Sigma-Aldrich, MO, USA) 
 
Kanamycin of 0.25 g was weighed out and dissolved in 5 ml of sterilized dH2O. The 
solution was filter sterilized and aliquoted into 500 µl working stocks. Kanamycin is light 
sensitive and aliquots were covered with foil and stored at -20 ̊C. 
 
6.1.6 Transformation buffer 
 
A 100 ml of transformation buffer was prepared with 100 mM CaCl2 (1.47 g), 10 mM 
PIPES-HCl (0.3 g) and 15 % Glycerol (15 ml) added to 70 ml of dH2O. The pH was 
adjusted to 7 with NaOH, the solution was made up to 100 ml with dH2O. The solution 
was autoclaved for 15 minutes at 121 ̊C and 1 kg/cm2 and stored at 4 ̊C. 
 
6.2 Small scale plasmid isolation buffers 
 
6.2.1 Buffer P1- resuspension buffer 
 
One liter of buffer P1 was prepared as follow: 6.06 g Tris base and 3.72 g Na2EDTA.2H2O 
was added to 800 ml of dH2O. The pH was adjusted to 8 with HCl and volume was made 
up to 1 L with dH2O. The buffer was autoclaved and allowed to cool down before adding 
100 mg of RNase A. Solution was mixed thoroughly and stored at 4 ̊C. 
 
6.2.2 Buffer P2- lysis buffer 
 
One liter of buffer P2 was prepared as follow: 8 g NaOH pellets and 10 g SDS was 
dissolved in 500 ml dH2O, volume was adjusted to 1 L with dH2O and stored at room 
temperature.  
 
6.2.3 Buffer P3- neutralization buffer 
 
One liter of buffer P3 was prepared as follow: 294.5 g potassium acetate was dissolved in 
500 ml dH2O. The pH was adjusted to 5.5 with approximately 300 ml of acetic acid and 
adjusted volume to 1 L with dH2O and stored at 4 ̊C.  
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6.2.4 QC buffer- wash buffer 
 
One liter of QC buffer was prepared as follow: 58.44 g NaCl and 10.46 g MOPS was 
dissolved in 800 ml dH2O. The pH was adjusted to 7 with NaOH, 150 ml of isopropanol 
was added and volume was adjusted to 1 L with dH2O and stored at room temperature. 
 
6.2.5 QF buffer- elution buffer 
 
One liter of QC buffer was prepared as follow: 73.05 g NaCl and 6.06 g Tris base was 
dissolved in 800 ml dH2O. The pH was adjusted to 8.5 with HCl, 150 ml of isopropanol 
was added and volume was adjusted to 1 L with dH2O and stored at room temperature. 
 
6.2.6 0.5 M EDTA 
 
To make 500 ml, 73.06 g EDTA was added to 300 ml of dH2O. The pH was adjusted to 
7.5 with NaOH pellets and then to pH 8 with 10 M NaOH. The final volume was adjusted 
to 500 ml with dH2O. 
 
6.2.7 1× TAE gel electrophoresis running buffer 
 
A 50 ×  TAE stock was prepared as follow: 242 g Tris base [tris(hydroxymethyl)-
aminomethane], 57.1 ml glacial acetic acid, 100 ml 0.5 M EDTA (pH 8) was dissolved in 
800 ml, the volume was adjusted to 1 L with dH2O. To make an 11.25 L of 1× TAE 
buffer, 225 ml of 50× TAE was added to 10 L of dH2O, volume was adjusted to 11.25 L. 
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6.3 Tissue culture reagents 
 
6.3.1 Dulbecco’s modified Eagles medium (DMEM) 
 
DMEM powder (Life Technologies, CA, USA) 
 
One liter of DMEM was prepared as follow: 13.38 g DMEM and 3.7 g NaHCO2 was 
dissolved in 500 ml of Sabex dH2O. The pH was adjusted to 6.7 with HCl and volume was 
adjusted to 950 ml. The medium was filter sterilised and stored at 4 ̊C. 
  
6.3.2 Eagle’s minimum essential medium (EMEM) (Life Technologies, CA, 
USA) 
 
Three liters of EMEM was prepared as follow: 28.59 g EMEM and 6.6 g NaHCO2 was 
dissolved in 500 ml of Sabex dH2O. The pH was adjusted to 6.7 with HCl and volume was 
topped up to final volume of 1 L. The medium was supplemented with 2mM L-glutamine 
(Lonza, Verviers, Belgium), filter sterilised and stored at 4 ̊C. 
 
6.3.3 Joklik modified Eagle’s minimum essential medium (EMEM) Eagle’s 
minimum essential medium (JEMEM) 
 
One liter of JEMEM was prepared as follow: 11.2 g JEMEM and 2 g NaHCO2 was 
dissolved in 500 ml of Sabex dH2O. The pH was adjusted to 6.7 with HCl and volume was 
topped up to 1000 ml. The medium was supplemented with 2 mM L-glutamine (Lonza, 
Verviers, Belgium), 5 % FCS, 100 units/ml Penicillin/Streptomycin and 0.1 mg/ml 
hygromycin filter sterilised and stored at 4 ̊C. 
 
6.3.4 1000× Penicillin and Streptomycin  
 
Stock solutions of a 1000× were prepared and filter sterilised. This equated to 100,000 
units/ml for penicillin and 100,000 µg/ml for streptomycin. For the supplementation of the 
medium, thus 0.5 ml 1000× stock into 500 ml culture medium, the working concentrations 
were penicillin 100 units/ml and streptomycin 100 µg/ml.  
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6.3.5 0.5× TrypLETM Express for trypsinisation (Life Technologies, CA, USA) 
 
TrypLETM Express (1×) was diluted 2-fold with Saline-EDTA solution (saline + 0.01 % 
EDTA). The mixture was filter sterilised and stored at 4 ̊C. 
 
6.3.6 Fetal Bovine serum (FBS) (Life Technologies, CA, USA) 
 
Gamma irradiated Fetal Bovine serum (FBS) was filter sterilized, aliquot into 50 ml 
working stocks and stored at -20 ̊C. Fifty milliliters of FBS was added to supplement the 
medium with 10 % FBS and 25 ml for 5 % FBS.  
 
6.3.7 4 mM Ferricyanide (Potassium Ferricyanide) 
 
Potassium Ferricyanide (1.317 g) was added to 20 ml of PBS and filter sterlised. To 
prevent precipitation, add PBS first. 
 
6.3.8 4 mM Ferrocyanide (Potassium Ferrocyanide) 
 
Potassium Ferrocyanide (1.689 g) was added to 20 ml of PBS and filter sterlised. To 
prevent precipitation, add PBS first. 
 
6.3.9 40 mg/ml X-Gal (5-bromo-4-chloro-3-indoyl-b-D-galactopyranoside) 
reagent (Sigma-Aldrich, MO, USA) 
 
X-gal (0.8 g) was added to 20 ml of DMSO.  
 
6.4 In vitro and In vivo reagents 
 
6.4.1 15 % 1:19 Bis-acrylamide:acrylamide gel (Merck Chemicals (Pty) Ltd, 
Darmstadt, Germany) 
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To 10 ml of dH2O 0.45 g of bis-acrylamide, 8.55 g acrylamide, 28.8 g Urea (~8 M) and 6 
ml 10× TBE pH 8 was added. The solution was made up to 60 ml with dH2O and 
dissolved in hot water. Before pouring of the gel 250 µl 1 % APS (0.1 g in 1 ml dH2O) and 
25 µl TEMED was added to the solution. 
 
6.4.2 TE buffer 
 
Added 10 mM Tris-HCl pH8 (1.58 g Tris-HCl in 600 ml dH2O, adjust pH to 8 and make 
up to 1L) and 1 mM EDTA to 1 L dH2O. 
 
6.4.3 Sephadex 
 
Five grams of Sephadex G-225 was added to 50 ml of TE buffer, the solution was stirred 
at room temperature overnight. Followed by centrifugation at 4000 rpm for 2 min. The TE 
buffer was poured off and 50 ml fresh TE buffer was added, repeated 2-3 times. The 
Sephadex was then resuspended in 50 ml TE buffer. 
 
6.4.4 10× TBE (500 ml) (Autoclave) 
 
Boric acid powder (27.5 g), 50 g Tris and 20 ml 0.5 M EDTA (pH 8) was added to 400 ml 
dH2O. The pH was adjusted to pH 8 and made up to a final volume of 500 ml with dH2O.  
 
6.4.5 20× SSC 
 
Added 3 M NaCl (175 g/L) and 0.3 M Na3C6H5O7.2H2O to dH2O, adjusted the pH to 7 
and made up to final desired volume. 
 
6.4.6 10 % SDS 
 
Ten grams of SDS was added to 100 ml dH2O. 
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6.5 Alignments 
 
6.5.1 Alignment of positive pTZ-Fluc clone sequence with parent sequence 
               51                                                  
Reference seq    CAG GTGTCCACTC CCAGTTCAAT  
 pTZ-Fluc seq                                               GAT CGATATCCAG GTGTCCACTC CCAGTTCAAT 
               101                                                 
Reference seq  TACAGCTCTT AAGGCTAGAG TACTTAATAC GACTCACTAT AGGCTAGCCT                                                                                                                                        
 pTZ-Fluc seq  TACAGCTCTT AAGGCTAGAG TACTTAATAC GACTCACTAT AGGCTAGCCT 
               151                                                
Reference seq  CGAGGATTGG GGACCCTGCG CTGAACATGG AAGACGCCAA AAACATAAAG 
 pTZ-Fluc seq  CGAGGATTGG GGACCCTGCG CTGAACATGG AAGACGCCAA AAACATAAAG 
               201                                                
Reference seq  AAAGGCCCGG CGCCATTCTA TCCGCTGGAA GATGGAACCG CTGGAGAGCA 
 pTZ-Fluc seq  AAAGGCCCGG CGCCATTCTA TCCGCTGGAA GATGGAACCG CTGGAGAGCA 
               251                                                
Reference seq  ACTGCATAAG GCTATGAAGA GATACGCCCT GGTTCCTGGA ACAATTGCTT 
 pTZ-Fluc seq  ACTGCATAAG GCTATGAAGA GATACGCCCT GGTTCCTGGA ACAATTGCTT 
               301                                                
Reference seq  TTACAGATGC ACATATCGAG GTGGACATCA CTTACGCTGA GTACTTCGAA 
 pTZ-Fluc seq  TTACAGATGC ACATATCGAG GTGGACATCA CTTACGCTGA GTACTTCGAA 
               351                                                
Reference seq  ATGTCCGTTC GGTTGGCAGA AGCTATGAAA CGATATGGGC TGAATACAAA 
 pTZ-Fluc seq  ATGTCCGTTC GGTTGGCAGA AGCTATGAAA CGATATGGGC TGAATACAAA 
               401                                                
Reference seq  TCACAGAATC GTCGTATGCA GTGAAAACTC TCTTCAATTC TTTATGCCGG 
 pTZ-Fluc seq  TCACAGAATC GTCGTATGCA GTGAAAACTC TCTTCAATTC TTTATGCCGG 
               451                                                
Reference seq  TGTTGGGCGC GTTATTTATC GGAGTTGCAG TTGCGCCCGC GAACGACATT 
 pTZ-Fluc seq  TGTTGGGCGC GTTATTTATC GGAGTTGCAG TTGCGCCCGC GAACGACATT 
               501                                                 
Reference seq  TATAATGAAC GTGAATTGCT CAACAGTATG GGCATTTCGC AGCCTACCGT 
 pTZ-Fluc seq  TATAATGAAC GTGAATTGCT CAACAGTATG GGCATTTCGC AGCCTACCGT 
               551                                                
Reference seq  GGTGTTCGTT TCCAAAAAGG GGTTGCAAAA AATTTTGAAC GTGCAAAAAA 
 pTZ-Fluc seq  GGTGTTCGTT TCCAAAAAGG GGTTGCAAAA AATTTTGAAC GTGCAAAAAA 
               601                                                
Reference seq  AGCTCCCAAT CATCCAAAAA ATTATTATCA TGGATTCTAA AACGGATTAC 
 pTZ-Fluc seq  AGCTCCCAAT CATCCAAAAA ATTATTATCA TGGATTCTAA AACGGATTAC 
               651                                                 
Reference seq  CAGGGATTTC AGTCGATGTA CACGTTCGTC ACATCTCATC TACCTCCCGG 
 pTZ-Fluc seq  CAGGGATTTC AGTCGATGTA CACGTTCGTC ACATCTCATC TACCTCCCGG 
               701                                                 
Reference seq  TTTTAATGAA TACGATTTTG TGCCAGAGTC CTTCGATAGG GACAAGACAA 
 pTZ-Fluc seq  TTTTAATGAA TACGATTTTG TGCCAGAGTC CTTCGATAGG GACAAGACAA 
               751                                                 
Reference seq  TTGCACTGAT CATGAACTC  CTCTGGATCT ACTGGTCTGC CTAAAGGTGT 
 pTZ-Fluc seq  TTGCACTGAT CATGAACTC  CTCTGGATCT ACTGGTCTGC CTAAAGGTGT 
               801                                                 
Reference seq  CGCTCTGCCT CATAGAACTG CCTGCGTGAG ATTCTCGCAT GCCAGAGATC 
 pTZ-Fluc seq  CGCTCTGCCT CATAGAACTG CCTGCGTGAG ATTCTCGCAT GCCAGAGATC 
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               851                                                 
Reference seq  CTATTTTTGG CAATCAAATC ATTCCGGATA CTGCGATTTT AAGTGTTGTT 
 pTZ-Fluc seq  CTATTTTTGG CAATCAAATC ATTCCGGATA CTGCGATTTT AAGTGTTGTT 
               901                                                
Reference seq  CCATTCCATC ACGGTTTTGG AATGTTTACT ACACTCGGAT ATTTGATATG 
 pTZ-Fluc seq  CCATTCCATC ACGGTTTTGG AATGTTTACT ACACTCGGAT ATTTGATATG 
               951                                                
Reference seq  TGGATTTCGA GTCGTCTTAA TGTATAGATT TGAAGAAGAG CTGTTTCTGA 
 pTZ-Fluc seq  TGGATTTCGA GTCGTCTTAA TGTATAGATT TGAAGAAGAG CTGTTTCTGA 
               1001                                               
Reference seq  GGAGCCTTCA GGATTACAAG ATTCAAAGTG CGCTGCTGGT GCCAACCCTA 
 pTZ-Fluc seq  GGAGCCTTCA GGATTACAAG ATTCAAAGTG CGCTGCTGGT GCCAACCCTA 
               1051                                               
Reference seq  TTCTCCTTCT TCGCCAAAAG CACTCTGATT GACAAATACG ATTTATCTAA 
 pTZ-Fluc seq  TTCTCCTTCT TCGCCAAAAG CACTCTGATT GACAAATACG ATTTATCTAA 
               1101                                               
Reference seq  TTTACACGAA ATTGCTTCTG GTGGCGCTCC CCTCTCTA AGGAAGTCGG 
 pTZ-Fluc seq  TTTACACGAA ATTGCTTCTG GTGGCGCTCC CCTCTCTA AGGAAGTCGG 
               1151                                               
Reference seq  GGAAGCGGT  TGCCAAGAG  GTTCCATCTG CCAGGTATCA GGCAAGGATA 
 pTZ-Fluc seq  GGAAGCGGT  TGCCAAGAG  GTTCCATCTG CCAGGTATCA GGCAAGGATA 
               1201                                              
Reference seq  TGGGCTCACT GAGACTACAT CAGCTATTCT GATTACACCC GAGGGGGATG 
 pTZ-Fluc seq  TGGGCTCACT GAGACTACAT CAGCTATTCT GATTACACCC GAGGGGGATG 
               1251                                               
Reference seq  ATAAACCGGG CGCGGTCGGT AAAGTTGTTC CATTTTTTGA AGCGAAGGTT 
 pTZ-Fluc seq  ATAAACCGGG CGCGGTCGGT AAAGTTGTTC CATTTTTTGA AGCGAAGGTT 
               1301                                               
Reference seq  GTGGATCTGG ATACCGGGAA AACGCTGGGC GTTAATCAAA GAGGCGAACT 
 pTZ-Fluc seq  GTGGATCTGG ATACCGGGAA AACGCTGGGC GTTAATCAAA GAGGCGAACT 
               1351                                               
Reference seq  GTGTGTGAGA GGTCCTATGA TTATGTCCGG TTATGTAAAC AATCCGGAAG 
 pTZ-Fluc seq  GTGTGTGAGA GGTCCTATGA TTATGTCCGG TTATGTAAAC AATCCGGAAG 
               1401                                               
Reference seq  CGACCAACGC CTTGATTGAC AAGGATGGAT GGCTACATTC TGGAGACATA 
 pTZ-Fluc seq  CGACCAACGC CTTGATTGAC AAGGATGGAT GGCTACATTC TGGAGACATA 
               1451                                               
Reference seq  GCTTACTGGG ACGAAGACGA ACACTTCTTC ATCGTTGACC GCCTGAAGTC 
 pTZ-Fluc seq  GCTTACTGGG ACGAAGACGA ACACTTCTTC ATCGTTGACC GCCTGAAGTC 
               1501                                               
Reference seq  TCTGATTAAG TACAAAGGCT ATCAGGTGGC TCCCGCTGAA TTGGAATCCA 
 pTZ-Fluc seq  TCTGATTAAG TACAAAGGCT ATCAGGTGGC TCCCGCTGAA TTGGAATCCA 
               1551                                               
Reference seq  TCTTGCTCCA ACACCCCAAC ATCTTCGACG CAGGTGTCGC AGGTCTTCCC 
 pTZ-Fluc seq  TCTTGCTCCA ACACCCCAAC ATCTTCGACG CAGGTGTCGC AGGTCTTCCC 
               1601                                               
Reference seq  GACGATGACG CCGGTGAACT TCCCGCCGCC GTTGTTGTTT TGGAGCACGG 
 pTZ-Fluc seq  GACGATGACG CCGGTGAACT TCCCGCCGCC GTTGTTGTTT TGGAGCACGG 
               1651                                               
Reference seq  AAAGACGATG ACGGAAAAAG AGATCGTGGA TTACGTCGCC AGTCAAGTAA 
 pTZ-Fluc seq  AAAGACGATG ACGGAAAAAG AGATCGTGGA TTACGTCGCC AGTCAAGTAA 
               1701                                               
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Reference seq  CAACCGCGAA AAAGTTGCGC GGAGGAGTTG TGTTTGTGGA CGAAGTACCG 
 pTZ-Fluc seq  CAACCGCGAA AAAGTTGCGC GGAGGAGTTG TGTTTGTGGA CGAAGTACCG 
               1751                                               
Reference seq  AAAGGTCTTA CCGGAAAACT CGACGCAAGA AAAATCAGAG AGATCCTCAT 
 pTZ-Fluc seq  AAAGGTCTTA CCGGAAAACT CGACGCAAGA AAAATCAGAG AGATCCTCAT 
               1801                                               
Reference seq  AAAGGCCAAG AAGGGCGGAA AGATCGCCGT GTAAA 
 pTZ-Fluc seq  AAAGGCCAAG AAGGGCGGAA AGATCGCCGT GTAAACTAGA GTCGACCCGG 
               1851                                               
Reference seq  GCGGCCGCTT CCCTTTAGTG AGG 
 pTZ-Fluc seq  GCGGCCGCTT CCCTTTAGTG AGGGATATCG ATC 
 
Figure 6.1: Alignment of Firefly luciferase reference sequence with the pTZFluc 
clone sequence. 
Sequences in red indicates the primers with engineered Eco RV site (blue sequence) used 
for the amplification of the Fluc sequence from pCI-neo-CMVFluc 
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6.6 Plasmid maps 
 
6.6.1 Empty pTZ57RInsTA cloning vector 
 
 
Figure 6.2: Plasmid map of pTZ57RInsTA plasmid used for the cloning of RNAi 
activators and Firefly luciferase.  
The linear plasmid is 2886 bp and has ampicillin resistance that act as a selection marker.  
 
6.6.2 Empty plasmid carrying a PEPCK promoter      
 
                             
Figure 6.3: Plasmid map of pBL-PEPCK-WL-SwaI-SpeI plasmid used for 
engineering of PEPCK RNAi activator and Fluc cassettes.  
Plasmid of 8381 bp with Ampicillin resistance as selection marker and a PEPCK promoter 
used for expression. 
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6.6.3 Empty recombinant Helper Dependent Adenoviral vector 
 
                            
A                                                                                B 
 
Figure 6.4: Plasmid map of p∆24.7E4 and p∆28E4CMVlacZ.  
A) HDAd Plasmid of 27459 bp with Kanamycin resistance as selection marker. B) The in 
vitro control plasmid of 32133 bp with Kanamycin resistance and a lacZ reporter gene 
expressed by a CMV promoter. 
 
6.6.4 Helper Dependent Adenoviral vector construction during cloning 
 
          
A                  B 
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 C   
Figure 6.5: Constructed HDAd vectors used for in vitro and in vivo analysis.  
A) HDAd plasmid with the anti-HBV pri-miR 31/5 expressed from a PEPCK promoter. B) 
HDAd plasmid with the anti-HBV pri-miR 31/589 expressed from a PEPCK promoter. C) 
HDAd plasmid with the reporter gene Firefly luciferase expressed from a PEPCK 
promoter.  
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6.7 Ethics clearance 
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